.svg)
AI-enabled clinical trial framework for end-to-end site recommendation and enrollment projection
Authors: Yip SS, Ruchlin I, Chawla J, Patel P, Auth K, Prior K, Zambon B, Dupont F, Tibbs C, Gurha P
Research Library
Publications
Explore publication summaries, author information, cancer focus areas, results, and links to full papers.
Real-world treatment patterns and clinical outcomes among cholangiocarcinoma patients treated with futibatinib or pemigatinib
Authors: Mahipal A, Christensen D, Penney K, Tepsick JG, Lan Z, Zhao R
Real-world effectiveness of MET inhibitors versus immunotherapy ± chemotherapy in 1L for patients with MET exon 14 skipping mutations in non-small cell lung cancer
Authors: Pradhan P, George R, Saini KS, J S, Veinalde R, Berraondo MI, Nunes Filho PRS, Dutra C, Batra U, Pecci F, Ricciuti B, Rider J, Cantini L
Biomarker-defined outcomes in metastatic clear cell renal cell carcinoma (mccRCC) receiving first-line (1L) immune checkpoint inhibitor-based therapy
Authors: Shah KU, Rider J, Pindale R, Zugman M, Jaime-Casas S, Abreu De Goes V, Moradi A, Salgia N, Zang PD, Castro DV, Mercier B, Zhang G, Li Y, Dizman N, ...
Association of mRNA COVID-19 vaccination near immune checkpoint inhibitor initiation with outcomes: A real-world analysis
Authors: Jiang C, Rider J, Kontoyiannis PD, Pandiri VK, Sadeghi N, Beg S
National perspectives on artificial intelligence use in cancer care: Confidence, adoption, and barriers
Authors: van Oort T, Colwell NA, Flora DB, Dicker AP, Fortune E, Bires J, Penberthy DR, Patt DA, Ajayi O, Chung C, Beg S, Parwani AV, Plotkin E
Contemporary real-world patterns of precision medicine in metastatic NSCLC
Authors: Gor J, Singh S, Aseem A, Kataria S, Naffakh N, Nguyen RH
Developing a pan-cancer foundation model for digital patient representation and clinical prediction across real-world oncology data
Authors: Parmar D, Ruchlin I, Thummagunti S, Gurha P, Yip SS
A multi-agent AI system integrating real-world data and competitive intelligence to generate automated trial eligibility recommendations
Authors: Yip SS, Thummagunti S, Auth K, Patel P, Prior K, Zambon B, Dupont F, Tibbs C, Chawla J, Gurha P
Systemic anticancer therapy in patients with de novo metastatic pancreatic adenocarcinoma: A real-world analysis
Authors: Bajaj P, Pradhan P, Wang Y, Karpes-Matusevich AR, Lan Z, Kent B, Gustafson WC, Graham J
Clinical outcomes among patients with metastatic non-small cell lung cancer (mNSCLC) who received immune checkpoint inhibitors (ICI) in first (1L) and second line (2L)
Authors: Wonsettler T, Fridman A, Karpes-Matusevich AR, Penney K, Hertler AA
Artificial intelligence–enabled analysis of unstructured EHR data for identification of actionable HER2-low breast cancer phenotypes
Authors: Patel A, Williford A, Ephraim A, Soto Pérez de Celis E, Hafez M, Brown TJ, Keswarpu P, Chandwani S, Rider J, Gurha P, Beg S, Joseph-Thomas J
Aragon-Ching JB, Pierattini C, Karovic S, Dvergsten E
Authors: Aragon-Ching JB, Pierattini C, Karovic S, Dvergsten E
PSA nadir–stratified outcomes of ARPI doublet and docetaxel triplet therapy in metastatic prostate cancer
Authors: Zugman M, Rider J, Pindale R, Shah KU, Moradi A, Jaime-Casas S, Zang PD, Salgia N, Abreu De Goes V, Sahu D, Ebrahimi H, Barragan-Carrillo R, Dizman ...
A US-based, retrospective, observational study of biomarker testing patterns across lines of therapy in patients with metastatic colorectal cancer
Authors: Kolhe R, Mukherjee V, Ng S, Beruti S, Quadri S, Liu K, Zagadailov E, Kamalakar R, Werner M, Sepulveda A
PD23-03 Clinical and molecular predictors of response to Lu-177-PSMA-617 in metastatic castration-resistant prostate cancer
Authors: Pe Benito RA, Mohammed SKM, Nathasingh B, Jairam S, Gordon S, Kong E, Chandwani S
Survival outcomes of cabazitaxel or subsequent androgen receptor pathway inhibitor (ARPI) in post-docetaxel/ARPI metastatic castration-resistant prostate cancer
Authors: Barata PC, Green L, Kim C, Hwang Y
5339 / 7 - Prevalence and distinct biological programs of small cell lung cancer molecular subtypes revealed by real-world clinico-genomics database
Authors: Luo Y, Wang L, Jahchan N, Ansell P, Zhao X, Zhao W
5351 / 19 - Epidemiology of folate receptor alpha expression in ovarian cancer by age, race/ethnicity, and histotype in a real-world, US-based clinicogenomic database
Authors: Arend RC, Hoskins KF, Guadamuz JS, Calip GS, Clarke MA, Choi YC, Zhang Q, Lastra RR, Strickland AL, Lynam SK
7857 / 9 - Multi-modal real-world data uncovers predictors of clinical response to TOP1i and optimizes ADC strategies in colorectal cancer
Authors: Tafazzol A, Cruz-González S, Shi X, Dezso Z, Kline DE, Chen J, Ansell PJ, Popovic R, Chen R, Samayoa J, Zhao X, Zhao W
1482 / 21 - A deep learning-based multimodal integration framework for clinical outcome prediction
Authors: Zhang B, Tian H, Bui T, Choi YC, Cai MH, Ansell P, Shrotre A, Chirieleison S, Kolahi K, Zhao X, Samayoa J, Zhao W
A0882 Subsequent treatment patterns and outcomes among patients with muscle invasive bladder cancer (MIBC) receiving neoadjuvant treatments: A real-world data analysis
Authors: Necchi A, Chang SS, Almeida L, Caplan EO, Pisano S, Pe Benito R, Bourla A, Sun R, Greshock J, Crist W, Kim W, Bhanvadia S
A0394 Molecular evolution and resistance mechanisms after Lu-177-PSMA-617 in metastatic castration-resistant prostate cancer
Authors: Pe Benito R, Mohammed S, Nathasingh B, Jairam S, Gordon S, Kong E, Chandwani S
Harmonizing logical observation identifiers names and codes (LOINC) codes and units in real-world oncology data: Method development and evaluation
Authors: Naliyatthaliyazchayil P, Stenerson T
Clinical outcomes of patients with metastatic colorectal cancer treated with trifluridine-tipiracil + bevacizumab by performance status
Authors: Nusrat M, Zhao R, He Y, Penney KL, Lan Z, Wang Y, Salimi T, Roby L, Andre T, Calleja E, Cann C
74 Real-world study characterizing patient characteristics, treatments, and unmet need in IO-ineligible patients with metastatic triple-negative breast cancer
Authors: Nguyen M, Shah R, Leclair B, Kariburyo-Yay F, Matusevich A, Mandora P
Androgen-receptor pathway inhibitors triplet therapy (ARAAT): Real-world outcomes in metastatic hormone-sensitive prostate cancer
Authors: Morgans AK, Khan N, Ghadessi M, McKay R, Chen G, George DJ
Trifluridine–tipiracil with and without bevacizumab in colorectal cancer
Authors: Nusrat M, Zhao R, Khan N, Wang Y, Penney KL, Cann CG, Salimi T
Emulating comparative oncology trials with real-world evidence studies (ENCORE): Process development and methodological considerations for oncology real-world data
Authors: Weberpals J, Schneeweiss S, Kehl KL, Rivera DR, Mishra-Kalyani P, Lerro CC, Larkins E, Narayan P, Curley R, Hahn G, Anand P, Natanzon Y, Belli AJ, ...
Real-world study of use patterns and clinical outcomes for patients with myelodysplastic syndrome initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents
Authors: Zeidan A, Zhao R, Tepsick JG, Lan Z, Salimi T
Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer
Authors: Sadetsky N, Prince P, Latimer H, Advani P, Smith-Gaziani D, Kaufman PA, Natanzon Y, Taylor A, Nguyen L, Freemantle N
Impact of real-world response to first-line immunotherapy and chemotherapy on subsequent treatment outcomes in patients with advanced or metastatic non-small cell lung cancer
Authors: Malhotra J, Viswanathan S, Mhatre SK, Dhillon IK, Patel R, Yohn N, Kariburyo-Yay F, Li X, Ricciuti B
Real-world treatment patterns, recurrence, and overall survival of patients with muscle-invasive bladder cancer undergoing radical cystectomy in U.S. oncology practice
Authors: Squires P, Coutinho F, Tepsick JG, Rogiers A, Ramamurthy C, Li H, Morgan TM
B057 Pathway-level molecular evolution and composite molecular genomic risk following Lu-177-PSMA-617 in metastatic castration-resistant prostate cancer
Authors: Pe Benito R, Mohammed SKM, Nathasingh B, Liao J, Khotskaya Y, Jairam S, Chandwani S
A020 Utilization of liquid biopsy in metastatic castrate resistant prostate cancer (mCRPC): patient characteristics, treatment selection, and mutational status
Authors: Hall MS, Penney KL, Liao J, Gordon S, Overstreet B, Rossi M, Rider JR
Biomarker prevalence in US patients with gastric/gastroesophageal junction adenocarcinoma (GEA) from real-world data
Authors: Rudra-Ganguly N, Luo H, Zhao W, Ganesan S, Predoiu R, Leibman R, Walker G, Ansell P
A multi-agent system for automated identification of competitive clinical trials in colorectal cancer
Authors: Yip SSF, Chawla J, Rossi MR, Chandwani S, Gurha P
Real-world clinical outcomes among metastatic colorectal cancer (mCRC) patients with liver metastases who received trifluridine/tipiracil (FTD/TPI) or FTD/TPI + bevacizumab (FTD/TPI+bev) combination therapy
Authors: Kim RD, Christensen D, Penney KL, Khan N, Yeola S, Pandiri VK, Zhao R
A United States-based real-world study on biomarker testing and rebiopsy rates among patients with non-small cell lung cancer across lines of therapy
Authors: Aggarwal C, Ng S, Kamalakar R, Beruti S, Simmons A, Beasley MB
Predictive modeling for survival outcomes in surgically resected pancreatic ductal adenocarcinoma: A comprehensive machine learning approach using real-world data
Authors: Ahmed KS, Issaka SM, Cher BAY, Marcinak CT, Zafar SN
1632P Predicting real-world overall survival in advanced melanoma using machine learning
Authors: Wang F, Hathi D, Chi L, Wu N, Nkhoma E, Harnett J, Salvati ME, Lewis K, Li Y
2796eP Seizure related 6 homolog (SEZ6) expression pattern and prognostic impact in a real-world cohort of patients with small cell lung cancer
Authors: Chiang AC, Wang L, Xu D, Luo A, Ansell PJ, Wang S
2477P Real-world prostate-specific antigen (PSA) response with darolutamide or abiraterone in metastatic hormone-sensitive prostate cancer (mHSPC) triplet therapy
Authors: Morgans AK, McKay RR, Khan N, Ghadessi M, Chen G, George DJ
873eP Real-world characteristics and outcomes of patients with third-line or later metastatic colorectal cancer: Magnetic-101 study results
Authors: Goetze TO, Xu Q, Ng S, Mudumba R, Kamalakar R, Quadri S, Desai K, Fang H, Patel M, Neagu Aristide MR, Jin Z
Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer
Authors: O'Shaughnessy J, Tolaney SM, Yardley DA, Hart L, Razavi P, Fasching PA, Janni W, Schwartzberg L, Kim J, Akdere M, McDermott C, Khakwani A, Pathak P, ...
Correlation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HR+/HER2- early breast cancer
Authors: Graff SL, Tolaney SM, Hart LL, Razavi P, Janni W, Schwartzberg LS, Danyliv A, Akdere M, Ferrusi I, Adhikary RR, O'Shaughnessy JA
Real-world treatment and outcomes for EGFR WT advanced/metastatic non-squamous non-small cell lung cancer: pooled analysis from project LUMINATE-101
Authors: Girard N, Xu Q, Camidge DR, Baijal S, Ng S, Kamalakar R, Ratajczak C, Alhasani H, Crawford S, Karve S, Lu S
Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: A United States electronic health records database analysis
Authors: Tarantino P, Rugo HS, Curigliano G, O'Shaughnessy JA, Janni W, Jhaveri K, Mouabbi J, Brufsky A, Hamilton E, O'Regan R, Santarsiero L, Akdere M, Ye F, ...
Real-world treatment patterns and survival in people with metastatic castration-resistant prostate cancer following metastatic hormone-sensitive disease between 2020 and 2023 in the United States
Authors: Raval AD, Chen G, Korn MJ, Bernthaler A, Constantinovici N, Freedland SJ
Quantification of information gained by linking claims data to an electronic health record cohort of patients with metastatic breast cancer
Authors: Geddes J, Katz J, Asiimwe A, Brookhart MA, Carroll C, Eldemir L, Mucaj V, Nolan K, Ntalla I, Nielson CM
Real-world treatment patterns among advanced non-small cell lung cancer patients in the US
Authors: Chen Y, Carlson A, Schommer J, Stenehjem D, Zhang D
Real-world characteristics, treatment modifications, and outcomes for patients with acute myeloid leukemia (AML) receiving hypomethylating agents (HMA) + venetoclax (VEN) as first-line treatment (1L)
Authors: Zeidan A, Wang Y, Yu R, Matusevich A, Zhao R
4522 Real-world monotherapy and combination usage of mogamulizumab among patients with mycosis fungoides or Sézary syndrome in the United States
Authors: Haverkos B, Chang C, Ristuccia R, DeGutis I, Chang Y, Friderici J, Rozati S
PP01.95 Real-world EGFR testing and adjuvant treatment patterns among patients with resected early-stage non-small cell lung cancer (NSCLC) in the United States
Authors: Kariburyo-Yay F, Liang Y, Simmons D, Miller V, Pye J, Ursino G
F3 Shifting treatment patterns in chromophobe renal cell carcinoma: A U.S. real-world data analysis
Authors: Zugman M, Rider JR, Dizman N, Jaime-Casas S, Castro DV, Mercier B, Salgia NJ, Shah K, Abreu de Góes V, Barragan-Carrillo R, Sahu D, Mandora PV, Hsu ...
390P Using AI methodology to stack and harmonize two U.S. EMR databases
Authors: Pierzynski J, Elashoff M, Lynn A, Mathur R, Chandwani S, Katz JA, Sadetsky N, McMahon P
338P Leveraging NSCLC foundation models to predict biomarker testing pattern
Authors: Yip SS, Parmar D, Ruchlin I, Thummagunti S, Chandwani S, Gurha P
SUNNIFORECAST trial design supported by real-world data in papillary renal cell carcinoma
Authors: Zugman M, Rider JR, Sahu D, Miller RS, Powles T, Choueiri T, Pal SK
HTA91 Correlation of intermediate clinical endpoints (ICES) for overall survival (OS) in localized or locally advanced prostate cancer (LPC/LAPC): Analysis of individual real-world data (RWD)
Authors: Jahn B, Krabbe LM, Merseburger AS, Shore ND, De Solda F, Nair S, Price M, Sacchi E, Schaeffer M, Tang A, McCallion J, Lin X, McCarthy SA, Mundle SD, ...
MSR69 Developing an EHR-based multifeature machine learning model to identify lung cancer subtype
Authors: Chandwani S, Priya V, Vaidya VP
Challenges in analyzing real-world evidence: Analysis of androgen deprivation therapy use for prostate cancer in the REASSURE study
Authors: Tran B, Yeh N, Gayle A, Holmes E, Hu J, Damineni S, Kebede N, Shore N
Real-world clinical characteristics, treatment patterns, and clinical outcomes in US patients with stage I-III resected NSCLC without known EGFR mutations: The RESECT study
Authors: Gray JE, Salomonsen RJ, Diaz Perez I, Wang A, Cai L, Wetherill G, Xiao Y, Fielden C, Georgoulia N
Overall survival in EGFR-mutant advanced NSCLC treated with first-line osimertinib: A cohort study integrating clinical and biomarker data in the United States
Authors: Sabari JK, Yu HK, Mahadevia PJ, Liu Y, Demirdjian L, Chen YH, Wang X, Passaro A
P2.06.18 Computational modeling of comprehensive genomic profiling to predict chemotherapy benefit in advanced NSCLC
Authors: Aggarwal C, Watson D, Nair P, Kumar A, Khandelwal S, Chauhan J, Khanna S, George S, Dey A, Patil M, Ganesh N, Purushottam R, Kulkarni S. G P, Lala ...
P1.11.59 Effect of IFNG expression levels on real-world survival outcomes in patients with metastatic non-small cell lung cancer receiving immunotherapy
Authors: Altoe M, Papillon-Cavanagh S, Poi M, Yip S, Oakland T, Rossi MR
113P Real-world treatment options for metastatic NSCLC patients following progression on chemo-immunotherapy
Authors: Cortellini A, P B A, Saini KS, George R, Di Vincenzo C, Nunes P, Novikov V, Huang H, Batra U, Chico I, Ramkissoon S, Russano M, Pecci F, Tiseo M, ...
15 Real-world evidence shows no survival advantage with contemporary first-line strategies in papillary renal cell carcinoma: A call for randomized trials
Authors: Zugman M, Rider JR, Dizman N, Castro DV, Mercier B, Shah K, Ebrahimi H, Jaime-Casas S, Barragan-Carrillo R, Sahu D, Vikramsinh Mandora P, Hsu J, Yip ...
Developing a digital twin framework for colorectal cancer outcome prediction and robust clinical trial simulation
Authors: Ruchlin I, Altoe M, Monberg M, Oakland T, Rossi M, Agarwal V, Chawla J, Gurha P, Yip SSF
STREAMLINE - Retrospective cohort study of FMS-like tyrosine kinase 3-mutated acute myeloid leukemia: Real-world treatment patterns and clinical outcomes of patients in first relapse or refractory diagnosis
Authors: Zeidan AM, Yu R, Wang Y, Lan Z, Grinblatt DL, Elsouda D, Spalding J, Block A, Touya M, Walker MS, Pandya BJ
Patients with advanced non-small cell lung cancer harboring MET alterations: A descriptive cohort study
Authors: Oksen D, Boutmy E, Wang Y, Stroh C, Johne A, Nisbett AR, Ryder A
(PB2488) Chart review study on the real-world cytopenia management of patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents
Authors: Zhao R, Wang Y, Dijkstra M, Wacheck V, Salimi T
(PB2779) Chart review study on dose modifications of patients with myelodysplastic syndrome treated with hypomethylating agents
Authors: Zhao R, Wang Y, Sano Y, Yeola S, Wachceck V, Salimi T
Comparison of outcomes for patients (pts) with R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with Bruton tyrosine kinase inhibitor (BTKi) and venetoclax from the TRANSCEND CLL 004 study versus a matched cohort of real-world (RW) pts
Authors: Wierda WG, Wang L, Liu FF, Tuazon SA, Perna SK, Gu F, Gu T, Yue L, De Benedetti M, Fang L, Chen L, Shadman M
Identification of predictive subphenotypes for clinical outcomes using real world data and machine learning
Authors: Pan W, Hathi D, Xu Z, Zhang Q, Li Y, Wang F
Treatment patterns and survival by race among men with metastatic castration-resistant prostate cancer (mCRPC) in the United States: A US electronic medical record database 2020-2023
Authors: Raval A, Chen G, Korn M, Freedland S
Real-world treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC) who previously progressed from metastatic hormone-sensitive prostate cancer (mHSPC) between 2020 to 2023 in the United States
Authors: Raval A, Chen G, Korn M, Bernthaler A, Constantinovici N, Freedland S
Biomarker testing and patterns of treatment in NSCLC patients: An IASLC analysis of ASCO CancerLinQ Discovery data
Authors: Behera M, Joseph G, Rupji M, Huang Z, Bunn B, Wynes MW, Switchenko J, Scagliotti GV, Tsao MS, Belani CP, Sequist LV, Ramalingam SS
Practice patterns and outcomes of conventional versus split-dose cisplatin in neoadjuvant ddMVAC in bladder cancer
Authors: Callihan EB, Kuna EM, Eule CJ, Kessler ER, Flaig TW
Survival outcomes among metastatic castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitor and docetaxel
Authors: Hwang Y , Wheeling T , Hatfield M, Kim C
Clinical use and outcomes of androgen-receptor pathway inhibitors triplet therapy for metastatic hormone-sensitive prostate cancer (ARAAT)
Authors: McKay R, Morgans A, Khan N, Constantinovici N, Chen G, Ghadessi M, Appukkuttan S, Jhaveri J, George D
Survival impact of adjuvant chemotherapy regimens for small (T1mi/a/b), node-negative (pN0), triple-negative breast cancer (TNBC)
Authors: Johnson K, Kim J, Slover B, House A, Hoeting B, Sandoval B, Thakur P, Johnson R, Roy A, Quiroga D, Bader G, Davenport A, Williams N, Cherian M, ...
Real-world side effects of targeted therapies: High-throughput association studies leveraging the CancerLinq Discovery lung cancer database
Authors: Vento J, Bastarache L, Chen Q, Osterman T
Leveraging real-world data sources for clinical oncology research: A review of studies published in ASCO publications
Authors: Lucido T, Greenberg M, Kania B, Karam J, Bates B
Analysis of ASCO clinical guidelines authorship and institutional representation using HemOnc.org
Authors: Jain S, Mohsin A, Herzog C, Mishra S, Cowan A, Schoen M, Yang P, Warner J
CO125 Adjusted comparison of amivantamab in combination with carboplatin plus pemetrexed from the PAPILLON study versus US real-world frontline treatments in patients with advanced NSCLC harboring EGFR exon 20 insertions
Authors: Schaeffer M, Lin X, Ngo N, Perualila NJ, Caparros EQ, Hales FG, Hultén A
HSD64 Real-world adjuvant nivolumab utilization in surgically treated muscle-invasive bladder cancer patients within U.S. community oncology practice
Authors: Squires P, Coutinho F, Tepsick JG, Stuart J, Ramamurthy C, Li H, Morgan TM
Recurrence and its association with overall survival (OS) in muscle-invasive bladder cancer (MIBC) patients undergoing radical cystectomy (RC): A real-world analysis
Authors: Squires P , Tepsick J , Coutinho F , Rogiers A, Ramamurthy C , Li H , Morgan T
Post-metastasis survival of patients with high-risk localized and locally advanced prostate cancer undergoing primary treatment in the United States: A retrospective study
Authors: Freedland SJ, Fernandes L, De Solda F, Buyukkaramikli N, Mundle SD, McCarthy SA, Labson D, Yang L, Pan F, Mir C
Prognostic score models for acquired resistance to frontline anti-programmed cell death protein 1/programmed death-ligand 1 therapy in metastatic non-small-cell lung cancer
Authors: Murray JC, Huang Q, Chen YC, Hu C, DiSantostefano RL, Wong C, Glatz L, Curran E, Villaruz LC, Hasan AN, Schoenfeld AJ
P32: Oncology trial emulation using real-world electronic health record data: Results of the Coalition to Advance Real-World Evidence through Randomized Controlled Trial Emulation (CARE) initiative
Authors: Levy N, Sheridan P, Campbell U, Lenis D, O'Doherty I, Estrin A, Gautam N, Zhen T, Belli A, Carrigan G, Chan A, Chen J, Chia V, Dhopeshwarkar N, ...
Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study
Authors: Chouaid C, Bosquet L, Knott C, Li Z, Schaeffer M, Lin X, Schioppa CA, Perualila NJ, Diels J, Caparros EQ, Galea F, Hultén A, Greystoke A
Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: A real-world evidence study
Authors: McCann KE, Osman N, Cannon J, Brent L, Wang Y, Tepsick J, Mandora PV, Miller V, Martin N, Kaklamani VG
Data stacking of RWD from two EMR databases in the United States using tokenization
Authors: McMahon P, Yu A, Allen PJ, Mathur R, Coutinho F, Katz J, Sadetsky N, Pierzynski J
[274] Epidemiology of MET gene mRNA expression in metastatic colorectal cancer: Analyses of a real-world clinicogenomic database
Authors: Calip GS, Choi YC, Cai MH, McNeill AM, Ng S, Xu Q, Vasilopoulos A, Wu S, Zhao W
Epidemiology of MET gene mRNA expression in metastatic colorectal cancer: Analyses of a real-world clinicogenomic database
Authors: Calip G, Choi YC, Cai M, McNeill A, Ng S, Xu Q, Vasilopoulos A, Wu S, Zhao W
Comorbidity assessment using integrated EHR and claims in a national oncology database
Authors: Chandwani S, Nathasingh B, Pe Benito R, Miller R
Integrated multi-setting real-world data to advance bladder cancer evidence generation
Authors: Pe Benito R, Nathasingh B, Joshi A, Ray H, Chandwani S, Morgan T
The value of integrating multi-care settings real world data for understanding prostate cancer management
Authors: Pe Benito R, Nathasingh B, Ray G, Chandwani S, Morgan T
6638 / 19 Identifying cancer germline variants associated with patient prognosis and response by applying clinico-genomics data
Authors: Wu S, Tsui M, McLaughlin RT, Dehal H, O'Donoghue CM, Qian J, Zhao K, Gillis BR, Rahimov F, Samayoa J, Zhao X, Zhao W
3395 / 15 Investigating clinical features and molecular mechanisms of long-term response and acquired resistance to immunotherapy in non-small cell lung cancer by applying real-world-data
Authors: Wu S, Zhao W, Zhang B, Choi C, Akhand SS, Zhang Q, Chen J, Ansell P, Chen R, Zhao X, Samayoa J
Pediatric cancer in the United States: A comparison of three data sources
Authors: Pace N, Huang T, Chen Q, Liu Y, Choi YC, McNeill A
Optimizing the identification and classification of non-small cell lung cancer (NSCLC): Validation and implementation of a patient cohort algorithm in claims databases
Authors: Viswanathan S, Mhatre SK, Forouzanfar M, Kolitsopoulos F, Patel R, Nambiar T, Reddy B, Peng M
Real-world use of accelerated approval oncology drugs subsequently withdrawn in the United States
Authors: Coutinho F, Karpes-Matusevich A, Miller V
The value of integrating urology and oncology real-world data for understanding prostate cancer management
Authors: Pe Benito R, Nathasingh B, Ray H III, Chandwani S, Morgan T
Real-world use of accelerated approval oncology drugs subsequently withdrawn in the United States
Authors: Coutinho F, Karpes-Matusevich A, Miller V
Comparing traditional NLP methods and LLM-based extraction for identifying biomarkers in lung cancer
Authors: Joseph-Thomas J, Keswarpu P, Singh N, Jiwani K, A B, Gurha P, Tiwari S, Yadav A, Samal V, Agarwal V, Lawrence M, Martin R
Electronic health records (EHR)-based machine learning (ML) approach to predict risk of progression to metastatic melanoma after initial diagnosis
Authors: Pindale R, Gemmler K, Pisano S, Tarhini A, Rider J
Machine learning model to forecast patient availability for oncology clinical trials
Authors: Kulkarni R, Vaidya V, Parmar D, Tibrewal A, Keswarpu P, Parikh R
RWD116 Training and validation of CARAai™: A multi LLM platform and data model to address oncology-specific challenges in clinical data extraction
Authors: Rider J, Vaidya VP, Jiwani K, Elton J, Culot L, Gurha P
EPH131 Estimating US cancer prevalence with community oncology EHR-based datasets via national benchmarks from SEER and NPCR
Authors: Ray H, Li J, Chandwani S, D'Ambrosio C
Behavior of test specificity under an imperfect gold standard: Findings from a simulation study and analysis of real-world oncology data
Authors: Walker MS, Slipski L, Natanzon Y
Real-world clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with trifluridine-tipiracil + bevacizumab by performance status
Authors: Nusrat M, Zhao R, Penney K, Lan Z, Wang Y, Cann C, Salimi T
Real-world patient characteristics and treatment patterns among cholangiocarcinoma patients treated with FGFR inhibitors
Authors: Mahipal A, Zhao R, Tepsick J, Lan Z, Penney K, Salimi T
Leveraging large language models to drive efficiency in clinical trial simulation
Authors: Yip SSF, Ruclin I, Elton J, Gurha P
Real-world clinical outcomes of trifluridine-tipiracil monotherapy (FTD-TPI) and FTD-TPI + bevacizumab combination therapy (FTD-TPI+bev) in 639 black patients (pts) with metastatic colorectal cancer (mCRC)
Authors: Nusrat M, Zhao R, Khan N, Wang Y, Pierre-Victor D, Tepsick J, R S, Cann C, Salimi T
Real-world clinical outcomes of patients (pts) with metastatic colorectal cancer (mCRC) who received trifluridine-tipiracil (FTD-TPI) monotherapy or FTD-TPI + bevacizumab (FTD-TPI+bev) combination therapy
Authors: Nusrat M, Zhao R, Khan N, Wang Y, Pierre-Victor D, Tepsick J, R S, Cann C, Salimi T
Real-world effectiveness of frontline treatments among patients with chronic lymphocytic leukemia: Results from ConcertAI
Authors: Roeker LE, Burke JM, Rhodes JM, Emechebe N, Jawaid D, Manzoor BS, Jensen CE, Ryland L, Liu Y, Marx SE, Sinai W, Roser J, Shadman M
Biomarkers of response in patients with gastric/gastroesophageal junction adenocarcinoma (GEA) treated with telisotuzumab adizutecan
Authors: Strickler J, Raimbourg J, Ghiringhelli F, Cohen J, Kitagawa C, Sharma M, Lee KH, O'Neil B, Rudra-Ganguly N, Luo X, Roberts-Rapp L, Predoiu R, Zhao W, ...
Folate receptor alpha (FRα; FOLR1) expression and persistence in ovarian cancer in clinical trial samples and real-world patient cohort
Authors: Swisher E, Zhang Q, Mehibel M, Masica D, Lakshmikanthan S, Deutschman E, Ansell P, Coleman R
Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals
Authors: Sledge GW Jr, Yoshino T, Xiu J, Helmstetter A, Ribeiro JR, Klimov S, Gilg B, Gao JJ, Elton J, Oberley MJ, Radovich M, Abraham J, Spetzler D
Patterns of concurrent chemotherapy selection in US patients undergoing trimodality therapy for muscle-invasive bladder cancer
Authors: Callihan E, Kuna EM, Robin TP, Eule CJ, Kim SP, Flaig TW
Real world evidence comparison of first-line (1L) immune-oncology(IO)/tyrosine kinase inhibitor (TKI) vs. IO/IO combination therapy in renal cell carcinoma (RCC)
Authors: Bolan P, Hui G, Low Y, Gombar S, Fan AC, Parikh DA, Shah S, Srinivas S, Khaki AR
Survival outcomes of apalutamide as a starting treatment: Impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS)
Authors: Maughan BL, Liu Y, Mundle S, Wang X, Nematian-Samani M, Karsh LI
656P Real-world (RW) frontline (1L) treatments (Txs) in patients (Pts) with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EFGR) exon 20 insertions (exon20ins) and adjusted comparisons versus PAPILLON study
Authors: Chouaid C, Bosquet L, Knott C, Li Z, Schaeffer M, Lin X, Schioppa C, Perualila N, Diels J, Quintero E, Galea F, Hulten A, Greystoke A
Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors
Authors: Naidoo J, Johnson DB, Doran C, Wang Y, Zhang Y, Le TK, Hopson S, Dreyfus B, Lal LS, Vyas C, Goldstein S, Izadi Z
Racial disparities in clinical trial enrollment among patients diagnosed with prostate cancer: A population-based cohort of oncology practices
Authors: Wiesen BM, Flaig TW, Gershman B, Konety B, Warren A, Kuna EM, Robin T, Kessler ER, Eule CJ, Breyer BN, Achua J, Kim SP
Clinical characteristics and treatment of patients with small cell prostate cancer: Analysis of a real-world cohort from an oncology database
Authors: Eule CJ, Warren A, Molina Kuna E, Robin TP, Gershman B, Kim SP, Flaig TW
P1-09-09 Disparities in second breast cancer events and survival persist despite optimal treatment in hormone-receptor positive breast cancer: Analysis of the real-world ASCO CancerLinQ dataset
Authors: Kantor O, Jones A, Mayer EL, Chavez-MacGregor M, King TA, Mittendorf EA
P3-03-12 Social determinants of health (SDOH) and Z code utilization among patients with breast cancer (BC)
Authors: Jones N, Blair A, Lipschultz E, Koskimaki J, Smither B, Miller R
P1-08-09 Real-world outcomes comparing 3-monthly with monthly goserelin implant in premenopausal women with breast cancer
Authors: McCann KE, Osman N, Cannon J, Brent L, Wang Y, Pierre-Victor D, Tepsick J, Mandora PV, Miller V, Martin N, Kaklamani VG
Evaluation of treatment strategies for patients with stage IIIA non-small cell lung cancer in the immunotherapy era
Authors: Alabaster A, Velotta JB, Tupper HI, Walker MS, Natanzon Y
Real-world treatment and clinical outcomes in patients with metastatic castration-resistant prostate cancer treated with olaparib in the United States
Authors: George DJ, Kariburyo-Yay F, Aggarwal H, Tepsick J, Yu R, Li W, Orji C, Ghate SR
5189 Real-world use patterns and clinical outcomes for myelodysplastic syndrome patients initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents
Authors: Zeidan AM, Zhao R, Pierre-Victor D, Wang Y, Tepsick J, Lan Z, Salimi T
4437 Real-world treatment patterns in patients with mycosis fungoides or Sezary syndrome treated with mogamulizumab in the United States: A retrospective database analysis
Authors: Haverkos BM, Chang C, Ristuccia R, Chang Y, Friderici J, Rozati S
4623 Mutations in the Bruton tyrosine kinase (BTK) gene in patients with chronic lymphocytic leukemia (CLL) receiving BTK inhibitors (BTKis)
Authors: Skarbnik AP, Danilov AV, Hoffmann M, Awan FT, Scarpa F, Davies C, Oakland T, Kovach M, Lilyquist J, Munugalavadla V, Yong ASM, Shetty V, Allan JN, ...
Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
Authors: Shadman M, Salkar M, Srivastava B, Karve S, Emond B, Gogna P, Manceur AM, Lafeuille MH, Rava A, Sun H, Howarth A, Tomicki S, Agatep B, Jones B, ...
Performance status classification of lung cancer patients by trained machine leaning
Authors: Takada S, Sato K, Onoue T, Sadachi Y, Matsushita Y
EP.11A.08 Real-world comparative effectiveness in advanced NSCLC and high PD-L1 with 1L immune checkpoint inhibitors ± chemotherapy
Authors: Hsu ML, Xia Q, Aggarwal S, Nkhoma E, R D, Hager T, Quek R, Feliciano J
Real-world clinical outcomes among patients with non-squamous advanced non-small cell lung cancer (aNSCLC) treated with docetaxel-based regimens post initial standard of care (SOC) in the United States
Authors: Shah R , Kariburyo-Yay F, Apple J, Lal LS , Miller V, Reuss JE
245P Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis
Authors: Tarantino P, Rugo HS, Curigliano G, O'Shaughnessy J, Janni W, Jhaveri K, Mouabbi JA, Brufsky AM, Hamilton EP, Oregan R, Santarsiero EC, Sum E, ...
1303P METPRO: Evaluating prognostic value of c-Met protein overexpression and concurrent biomarker presence
Authors: Le X, Aggarwal C, Simmons A, Crawford SA, Ng S, Chen C, Karve S, Stein S, Woll K, Ansell PJ, Mistry A, Bryant D, Wistuba II
1352P Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy
Authors: Russano M, Cantini L, P B A, George R, Nunes P, Tolba K, Dutra C, Chico I, Cortellini A, Pecci F, Alessi JV, Ricciuti B, Ramkissoon S, Aerts JG, ...
Calibrating observational health record data against a randomized trial
Authors: Merola D, Campbell U, Lenis D, Schneeweiss S, Wang S, Madsen A, Carrigan G, Chia V, Ovbiosa OE, Pinheiro S, Pace N, Bruno A, Stewart M, Khosla S, ...
Emulations of oncology trials using real-world data: A systematic literature review
Authors: Rider JR, Wasserman A, Slipski L, Carrigan G, Harvey R, Jiao X, McRoy L, Pace ND, Becnel L, Bruno A, Eckert JC, Hodgkins P, Jain P, Merola D, Ovbiosa ...
Real-world treatment patterns and outcomes in patients with HR+/HER2− metastatic breast cancer treated with chemotherapy in the United States
Authors: Tolaney SM, Punie K, Carey LA, Kurian AW, Ntalla I, Sjekloca N, Shah A, Rehnquist MK, Stokes M, Fraeman K, Verret W, Jhaveri K
Treatment intensification in metastatic hormone-sensitive prostate cancer: An analysis of real-world practice patterns from the CancerLinQ Database
Authors: Eule CJ, Kuna EM, Robin TP, Gershman B, Flaig TW, Kim SP
RWD23 Addition of open administrative claims significantly improves capture of mortality in electronic health record (EHR) - focused real-world data (RWD)
Authors: Slipski L, Dub B, Yu Y, Walker M, Natanzon Y
Evaluation of real-world tumor response derived from electronic health record data sources: A feasibility analysis in mNSCLC patients treated with chemotherapy
Authors: McKelvey BA, Garrett-Mayer E, Rivera DR, Alabaster A, Andrews HS, Bond EG, Brown TD, Bruno A, Damato L, Espirito JL, Fernandes LL, Hansen E, Kluetz ...
194: Immune-related adverse events of anti-PD-(L)1 immunotherapy with and without chemotherapy in patients with advanced non-small cell lung cancer: A real-world evidence study
Authors: Shao P, Archambault AN, Hampp C, Sobel RE, Asubonteng J, Geba GP, Pillai AB
1361 Quantification of information gained by linking claims data to an EHR cohort of US metastatic breast cancer (mBC) patients
Authors: Geddes J, Katz J, Asiimwe A, Brookhart MA, Carroll C, Eldemir L, Mucaj V, Nolan K, Ntalla I, Nielson CM
435 Identifying the period of heightened risk for adrenal insufficiency in patients with advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors
Authors: Archambault A, Breskin A, Okoye E, Ghattas M, Byrne SE, Wang J, Asubonteng J, Hampp C
1433 Pediatric cancer in the United States: A comparison of two data sources
Authors: Pace ND, Huang TH, Chen Q, Liu Y, Choi YC, McNeill A
803 Representativeness of race, ethnicity and social determinants of health in patients with advanced non-small cell lung cancer via linkage of real-world electronic health records, administrative claims, and consumer financial data
Authors: Calip GS, Choi YC, Cai M, Liede A, Monegro N, McNeill A
1231 Unlocking insights: Lesson learned from the tokenization of a psoriasis trial
Authors: D'Andrea E, Choi YC, Zhang D, Tepsick J, R S, Smith H, Pinheiro S, Liede A
242: A combined machine learning and natural language processing approach to determine metastatic date through integrated temporal modeling
Authors: Priya V, Bhattacharyya U, Chandwani S, Ray G, Tankala S, Swaminathan K, Cohen J, Vaidya V
A retrospective analysis of treatment patterns, overall survival, and real-world disease-free survival in early-stage non-small cell lung cancer following complete resection
Authors: Hu X, Chirovsky D, Walker MS, Wang Y, Kaushiva A, Tepsick J, Samkari A
Seeking American Society of Clinical Oncology-QualityOncology Practice Initiative (ASCO-QOPI) certification in anorthern New England rural health system and cancer care network
Authors: Perrey HM, Taylor E, Cropp BF, Bumpus MJ, Lessard S, Pretorius JA, Angus JH, Duperreault MF, Snow A, Wang D, Curtis M, Couture LA, Adolphson DR, ...
Prognosis and conditional survival among women with newly diagnosed ovarian cancer
Authors: Szamreta EA, Monberg MJ, Desai KD, Li Y, Othus M
Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
Authors: Sukumar JS, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, Ramaswamy B, Wesolowski R, Cherian M, Stover DG, Gatti-Mays M, Pariser A, Sudheendra ...
The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer
Authors: Johnson KCC, Ni A, Quiroga D, Pariser AC, Sudheendra PK, Williams NO, Sardesai SD, Cherian M, Stover DG, Gatti-Mays M, Ramaswamy B, Lustberg M, ...
EGFR mutation testing, treatment and survival in stage I–III non-small-cell lung cancer: CancerLinQ Discovery database retrospective analysis
Authors: Muthusamy B, Berktas M, Li J, Thomas DS, Sun P, Taylor A, Pennell NA
Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States
Authors: Kalinsky K, Spring L, Yam C, Bhave MA, Ntalla I, Lai C, Sjekloca N, Stwalley B, Stokes M, Taylor A, Nanda R
Assessing feasibility of using RWD to support biosimilar development: Rituximab use in US patients with follicular lymphoma
Authors: Flanigan JA, Nisbett AR, Lal LS, Arani R, Li EC
Comparing prospectively assigned trial and real-world lung cancer patients
Authors: Walker B, Ray HE, Shao P, D'Ambrosio C, White C, Walker MS
Rapid and deep prostate-specific antigen (PSA) response to apalutamide plus ADT and survival in metastatic castration-sensitive prostate cancer (mCSPC) in real world practice in the US (OASIS Project)
Authors: Maughan BL, Liu Y, Mundle S, Wang X, Karsh LI
A real-world study on biomarker retesting among patients with non-small cell lung cancer and disparity in outcomes
Authors: Crawford S, Aggarwal C, Ng S, Xu Q, Simmons A, Gulati A, Beasley MB
Representativeness of race, ethnicity and social determinants of health in patients with advanced non-small cell lung cancer via linkage of real-world electronic health records, administrative claims, and consumer financial data
Authors: Calip GS, Choi YC, Cai M, Liede A, Monegro N, McNeill A
Real-world study on the characteristics, post-nephrectomy journey, and outcomes of patients with early-stage renal cell carcinoma based on risk groups
Authors: Karam JA, Bhattacharya R, Ogbomo A, Gautam S, Yu R, Sundaram M, Imai K, Chhabra J, Haas NB
Electronic clinical quality measure (eCQM) concordance and quality care disparities among patients with breast cancer (BC)
Authors: Jones N, Lipschultz E, Blair A, Smither B, Koskimaki J, Miller RS
Disparities in patients with HER2-positive breast cancer receiving optimal treatment: Analysis of the real-world ASCO CancerLinQ dataset
Authors: Kantor O, Jones AN, Mayer EL, Chavez-MacGregor M, King TA, Mittendorf EA
Predicting real-world overall survival for post-operative pancreatic ductal adenocarcinoma: An ASCO CancerLinQ Discovery analysis
Authors: Ahmed KS, Issaka SM, Marcinak CT, Zafar SN
Real-world baseline treatment patterns and overall survival (rwOS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in the United States
Authors: Kariburyo-Yay F, George DJ, Aggarwal H, Tepsick JG, Yu R, Li W, Orji C, Lal LS, Ghate SR
Dynamic machine learning model to forecast patient availability for clinical trials
Authors: Kulkarni R, Vaidya VP, Parmar D, Tibrewal A, Parikh RB
A prospective study comparing AI-based clinical trial eligibility screening with traditional EMR-based screening
Authors: Joseph-Thomas J, Green C, Tibrewal A, Dupont F, Flach J, Goldstein A, Vaidya VP, Kulkarni R, Parikh RB
Efficient site selection for clinical trials using simulated annealing
Authors: Ruchlin I, Govil V, Samar D, Chawla J, Gurha P
MP51-18 Population-based trends and outcomes for cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States
Authors: Wiesen B, Achua J, Warren A, Gershman B, Eule C, Kim S
MP31-17 Variation in genomic testing amongst localized prostate cancer patients undergoing radical prostatectomy or radiation therapy: Results from a population-based cohort
Authors: Wiesen B, Achua J, Warren A, Konety B, Robin T, Gershman B, Flaig T, Eule C, Kim S
Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer
Authors: Struebing A, McKibbon C, Ruan H, Mackay E, Dennis N, Velummailum R, He P, Tanaka Y, Xiong Y, Springford A, Rosenlund M
An emulation of the KEYNOTE-189 trial using electronic health records
Authors: Merola D, Campbell U, Lenis D, Madsen A, Schneeweiss S, Wang S, Carrigan G, Taylor A, Huang J, Chia VM, Ovbiosa O, Pinheiro S, Pace ND, Bruno A, ...
Budget impact of pirtobrutinib for patients with mantle cell lymphoma (MCL) or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in the United States (US)
Authors: Winfree KB, Zhang KH, Muehlenbein CE, Panjic EH, Ale-Ali A, Graham CN
Comparative analysis of different methods of disease progression data capture in patients with metastatic castration-resistant prostate cancer
Authors: Nguyen J, Byrne C, Tang J, Patel J
Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer
Authors: Divan HA, Bittoni MA, Krishna A, Carbone DP
Proportional randomization method to identify index line of therapy in externally controlled trials
Authors: Cui Z, Khanal M, Chen Y, Li X, Winfree K
Integrating real-world histopathological and clinicogenomic data from 1799 lung cancer patients by applying unsupervised deep learning
Authors: Wu S, Zhao Y, Luo H, Kolahi K, Bui T, Shi X, Shrotre A, Liede A, Zhao X, Samayoa J, Zhao W
Harness the power of real-world-data for oncology target and biomarker research: A case study by applying clinic-genomics data for 2,659 lung cancer patients and beyond
Authors: Wu S, Zhao W, Choi C, Cai M, Ansell P, Liede A, Chen R, Zhao X, Samayoa J
EP.12A.03 Overall survival after treatment with first-line osimertinib for EGFR-mutant advanced NSCLC in the US
Authors: Sabari JK, Yu HA, Mahadevia P, Liu Y, Demirdjian L, Sultan AA, Chen YH, Wang X, Passaro A
KRAS co-mutational landscape dictates treatment outcomes in pancreatic cancer (PC) patients
Authors: Ghosh P, George R, Singh N, Agrawal S
Identifying the genetic basis for resistance to aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients
Authors: Singh N, Agrawal S
Survival outcomes of APA as a starting treatment: Impact in real-world patients with mCSPC (OASIS)
Authors: Maughan BL, Mundle S, Nematian-Samani M, Wang X, Du S, Liu Y, Karsh LI
Real-world homologous recombination repair mutation (HRRm) testing patterns in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in the United States
Authors: George DJ, Kariburyo-Yay F, Aggarwal H, Tepsick JG, Yu R, Li W, McLaurin KK, Orji C, Lal LS, Ghate SR
Real-world treatment patterns, testing patterns, and clinical outcomes of first-line (1L) therapy for metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (mGC/GEJC/EAC)
Authors: Kakehi S, Betts KA, Nie X, Kitchen SA, Ray S
Predicting progression-free survival (PFS) in first-line (1L) immune checkpoint inhibitor (ICI)-treated patients (pts) with advanced non-small cell lung cancer (aNSCLC): Machine learning (ML) application in real-world data
Authors: Hathi DK, Harnett J, Wu N, Xu Z, Pan W, Hager TG, Quek RGW, Aggarwal S, Kim Y, Rietschel P, Seebach F, Wang F, Li Y
Identifying co-mutational signatures in STK11 mutated advanced non-small cell lung cancer (aNSCLC) patients that help overcome poor response to immune checkpoint inhibitors (ICI’s)
Authors: Singh N, Agrawal S
Characteristics, treatment patterns, and outcomes in patients with high-risk locally advanced cervical cancer
Authors: Coutinho F, Gokhale M, Doran C, Monberg M, Yamada K, Chen L
PO1-17-07 Invasive disease-free survival as a surrogate for overall survival in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative early breast cancer: a real-world analysis
Authors: Graff S, Tolaney S, Hart L, Razavi P, Janni W, Schwartzberg L, Danyliv A, Payan JCM, Ferrusi I, Adhikary RR, O'Shaughnessy J
Real-world outcomes in metastatic HR+/HER2-, HER2+ and triple negative breast cancer after start of first-line therapy
Authors: DeClue RW, Fisher MD, Gooden K, Walker MS, Le TK
Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2− MBC in the real world
Authors: Kruse M, Smyth EN, Bowman L, Gautam S, Guimaraes CM, Nisbett AR, Fisher MD, Cui ZL, Sheffield KM, Kalinsky K
The RESECT study: Factors associated with overall survival (OS) and relapse-free survival (RFS) among patients with stages I–III resected NSCLC without known EGFR mutations
Authors: Gray JE, Salomonsen R, Georgoulia N, Perez ID, Wang A, Cai L, Wetherill G, Xiao Y, Fielden C, Altorki NK
Pitfalls with analyses of real-world data: A look at ASCO’s CancerLinQ Discovery multiple myeloma dataset
Authors: Shou KJ, Thornton JA, Sunderland K, DeStefano C
Uptake and efficacy of immuno-oncology combinations in metastatic renal cell carcinoma in the United States: Evidence from the ASCO CancerLinQ Discovery database
Authors: Vento J, Haake SM, Beckermann K, Rini BI, Chen YW
Implementing a BRAF biomarker electronic clinical quality measure in CancerLinQ
Authors: Drumheller C, Barzi A, Koskimaki J
Case studies for overcoming challenges in using big data in cancer
Authors: Sweeney SM, Hamadeh HK, Abrams N, Adam SJ, Brenner S, Connors DE, Davis GJ, Fiore LD, Gawel SH, Grossman RL, Hanlon SE, Hsu K, Kelloff GJ, Kirsch IR, ...
Challenges to using big data in cancer
Authors: Sweeney SM, Hamadeh HK, Abrams N, Adam SJ, Brenner S, Connors DE, Davis GJ, Fiore L, Gawel SH, Grossman RL, Hanlon SE, Hsu K, Kelloff GJ, Kirsch IR, ...
Evaluation of cost-effectiveness of adjuvant osimertinib in patients with resected EGFR mutation-positive non-small cell lung cancer
Authors: Verhoek A, Cheema P, Melosky B, Samson B, Shepherd FA, de Marinis F, John T, Wu YL, Heeg B, Van Dalfsen N, Bracke B, Miranda M, Shaw S, Moldaver D
Real-world big-data: Strengths and weaknesses of ASCO's CancerLinQ® discovery multiple myeloma dataset
Authors: DeStefano CB, Thornton JA , Gibson SJ , Pham K, Miller RS , Sunderland K
Health data sharing perspectives of patients receiving care in CancerLinQ-participating oncology practices
Authors: Jagsi R, Suresh K, Krenz CD, Jones RD, Griffith KA, Perry L, Hawley ST, Zikmund-Fisher B, Spector-Bagdady K, Platt J, De Vries R, Bradbury AR, Bansal ...
Multiple myeloma in adolescent and young adults: An ASCO CancerLinQ and SEER analysis
Authors: Gibson S, Thornton J , Sunderland K, Pham K, DeStefano C
Prognostic impact of second primary malignancies in multiple myeloma: An ASCO CancerLinQ discovery analysis of the modern era
Authors: Gibson SJ, Cooper JD, Pham K, Sunderland K, Thornton JA, DeStefano CB
Real-world pitfalls of analyzing real-world data: A cautionary note and path forward
Authors: Cooper JD, Shou K, Sunderland K, Pham K, Thornton JA, DeStefano CB
Natural history and real-world treatment outcomes for non-small cell lung cancer patients with EGFR Exon 20 Insertion Mutation: An IASLC- ASCO CancerLinQ Study
Authors: Behera M, Jiang R, Huang Z, Bunn B, Wynes MW, Switchenko J, Scagliotti GV, Belani CP, Ramalingam SS
Real-world progression-free survival and treatment patterns for t(11;14) positive patients with multiple myeloma with at least 2 prior lines of treatment
Authors: Girvan A, Martins D, Yu J, Ng S, Kamalakar R, Zafar F, Tulsian S, Cornell RF, Samir M
Real-world treatment patterns and healthcare resource utilization in patients with Waldenström macroglobulinemia initiating first-line treatment with ibrutinib or zanubrutinib
Authors: Paludo J, Sarosiek SR, von Keudell GR, Salkar M, Zhou S, Kim S, Cheng N, Pacia M, Karve S, Castillo JJ
MDS-567 Real-world analysis of a large electronic medical record database of patients with higher-risk myelodysplastic neoplasms (HR MDS): Treatment profiles, clinical effectiveness, and key adverse event rates
Authors: Shah R, Thanataveerat A, Rudraraju R, Curtis K, Jhaveri TZ, Askin G, Irwin DE, Pierzynski J, Hogea C, Sabate EJ, Sali AP, Williamson M
Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative (HR+/HER2−) early breast cancer (EBC): A US database analysis
Authors: Graff SL, Tolaney SM, Hart LL, Razavi P, Fasching PA, Janni W, Schwartzberg LS, Lanoue B, Salas TR, Khakwani A, McDermott C, Pathak P, O'Shaughnessy J
Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients
Authors: Betof Warner A, Tarhini A, Kang B, Nakasato A, Ling YL, Shah R, Tang J, Patel J
Adverse events and clinical outcomes in patients treated with PD-(L)1 blockade for advanced non-small-cell lung cancer
Authors: Zhang Y, Doran C, Le TK, Dreyfus B, Kola N, Sylvester BE, Lal L, Penrod JR, Meadows Shropshire S
Abstract A131: Clinical characteristics and outcomes of Black patients with multiple myeloma compared with other races
Authors: Spence S, Yu J, Girvan A, Ng S, Li S, Zafar F, Yellow-Duke A, Cornell RF
Post-metastasis survival in high-risk localised and locally advanced prostate cancer patients undergoing primary treatment in the United States: A retrospective study
Authors: Freedland S, Fernandes L, De Solda F, Buyukkaramikli N, Mundle SD, McCarthy SA, Labson D, Yang L, Pan F, Mir C
Clinical and economic impact of recurrence in early-stage non-small-cell lung cancer following complete resection
Authors: West H, Hu X, Chirovsky D, Walker MS, Wang Y, Kaushiva A, Tepsick J, Samkari A
Real-world treatment patterns and outcomes of patients with metastatic nonsquamous non-small cell lung cancer after progression on standard-of-care therapy in the United States
Authors: Divan HA , Bittoni MA, Krishna A, Carbone DP
269 Impact of ibrutinib dose reduction on duration of therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
Authors: Shadman M, Karve S, Patel S, Rava A, Sun H, Howarth A, Tomicki S, Srivastava BP, Stephens DM
Machine learning (ML) on real-world data (RWD) of front-line (1L) metastatic castration resistance prostate cancer (mCRPC) patients for dynamic prediction of time to tx discontinuation (TTD)
Authors: Jain P, Hathi DK, Honarvar H, Das RK
19P Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis
Authors: Girard N, Leighl N, Ohe Y, Kim TM, Demirdjian L, Bourla AB, Sultan AA, Mahadevia P, Bauml JM, Sabari J
Augmentation of real-world mortality data in the electronic medical record: Assessing the impact on overall survival estimates in multiple myeloma
Authors: Liu P, Lan Z, Walker B, Ray HE, Smith H
573P LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Authors: Cho BC, Xu Q, Ng S, Goldman JW, Girard N, Planchard D, Baijal S, Kamalakar R, Blot V, Alhasani H, Karve S, Lu S
Site of metastasis (SoM) and its impact on clinical outcomes in 8 cancer cohorts
Authors: George R, Singh N, Vidal L, Hajek E, Skalska D, Saini KS, Agrawal S
Development of natural language processing (NLP) models for extracting key features from unstructured notes to create real-world data (RWD) assets for clinical research at scale
Authors: Agrawal S, George R, Vaidya VP, Chakkrapani S, Prajapati R, Tankala S, Parmar D, Lakkimsetty VPS, Bhardwaj T, Ashwani A, Mendonca E, Narayanan B, ...
Enhancement in line of therapy (LoT) derivation from real-world data (RWD) from electronic health records (EHR) via integration of medical claims data
Authors: Agrawal S, B AP, George R, Singh N, Soni M, Chakkrapani S, Priya V, Vaidya VP
An adjusted treatment comparison comparing amivantamab versus real-world clinical practice in Europe and the United States for patients with advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations
Authors: Chouaid C, Bosquet L, Girard N, Kron A, Scheffler M, Griesinger F, Sebastian M, Trigo J, Viteri S, Knott C, Rodrigues B, Rahhali N, Cabrieto J, Diels ...
Supporting the use of RWD in oncology drug development, Session 1: Establishing a framework for evaluating real-world response
Authors: Garrett-Mayer E, Bruno A, Robert N, Schwartz L, Mishra-Kalyani P, Natanzon Y
Comparative effectiveness of abiraterone and enzalutamide in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): A retrospective cohort study in a large database of deeply curated EHR real-world data (RWD) from community oncology practices in the US
Authors: An H, Schoen MW, Rider J, Schorer AE, Ken J, Chen L, Alabaster A, Natanzon Y
Improving real-world mortality data quality in oncology research: Augmenting electronic medical records with obituary, Social Security Death Index, and commercial claims data
Authors: Shao P, Tepsick JG, Walker B, Ray HE
957 Machine learning (ML) model for prediction of pneumonitis using real-world data (RWD) on immune checkpoint inhibitor (ICI)-treated advanced non-small cell lung cancer (aNSCLC)
Authors: Hall H, Mueller J, Cai MH, Liu Y, Liede A, Das R, Hathi D
3358 Real-world evaluation of outcomes in relapsed/refractory multiple myeloma patients that are triple-class exposed after receiving 2 or more prior lines of therapy
Authors: Radwanski K, Yu J, Pierce K, Talati C, Stricker S, Jiao S, Bueno O
5100 Machine learning approach to understand real-world treatment in patients with higher-risk myelodysplastic syndromes
Authors: Priya V, Vaidya VP, Agrawal S, Singh N, Chatra K, Parmar D, Yan R, Das RK, Haririfar M, McMahon P, Williamson M, Sadek I, Hogea C
5143 Impact of real-world treatment sequencing patterns on time to next treatment among patients with chronic lymphocytic leukemia in the United States
Authors: Chanan-Khan AA, Challagulla S, Kaushiva A, Miller V, Wang Y, Smith H, Yang K
Racial and ethnic representation in large B-cell lymphoma trials and real-world databases
Authors: Munoz J, Mutebi A, Wang T, Zhang G, Yu J, He J, Chibber A, Kamalakar R, Jun MP, Adejumo K, Yang S, Kalsekar A
Machine learning (ML) model for prediction of pneumonitis using real-world data (RWD) on immune checkpoint inhibitor (ICI)-treated advanced non-small cell lung cancer (aNSCLC)
Authors: Hathi DK, Hall H, Mueller J, Cai MH, Liu Y, Liede A, Das RK
Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)
Authors: Jin R, Ogbomo AS, Accortt NA, Lal LS, Bishi G, Sandschafer D, Goldschmidt JH
Real-world (RW) use patterns, effectiveness, and tolerability of sacituzumab govitecan (SG) for second-line (2L) and later treatment of metastatic triple-negative breast cancer (mTNBC)
Authors: Kalinsky K, Spring L, Yam C, Taylor A, Sjekloca N, Kaushiva A, Lai C, Ntalla I, Nanda R
Picturing progression: A new role of whole slide imaging in comprehensive clinical genomic datasets
Authors: Sweeney EG, Wang YJ, Picard J, Abraham J, Amidi E, Rossi MR, Klimov S, D'Ambrosio C, Chen M, Elton J, Sledge G
Genomic landscape of patients with non-small cell lung cancer (NSCLC)
Authors: Singh NK, Saini KS, Chakkrapani S, Severson E, Nagaraj N, Ramkissoon S, Chico I, Aguilo A, George R, Vidal L, Agrawal S
Real-world treatment (Tx) patterns in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US)
Authors: Punie K, Jhaveri , Tolaney SM, Ntalla I, Shah A, Sjekloca N, Fraeman K, Carey LA
Real-world analysis of a large electronic medical record database of patients with higher-risk myelodysplastic syndromes (HR MDS): Treatment profiles, clinical effectiveness, and key adverse events
Authors: Shah R, Thanataveerat A, Rudraraju R, Curtis K, Jhaveri TZ, Askin G, Irwin D, Dinoso J, Hogea C, Sabate EJ, Radford M, Sali AP, Williamson M
Real-world clinical outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US)
Authors: Tolaney SM, Punie K, Kurian AW, Ntalla I, Verret W, Sadetsky N, Sjekloca N, Stokes M, Jhaveri KL
Real-world outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) in 2L+ in the United States (US)
Authors: Kalinsky K, Spring L, Yam C, Taylor A, Sjekloca N, Kaushiva A, Lai C, Ntalla I, Nanda R
P572: Real-world management and outcomes for newly diagnosed AML patients initiating Venetoclax and hypomethylating agents in US community practice
Authors: Wang Y, McNeill AM, Doran C, Cain LE, Liu Y, Lan Y, Cheng WH, Pullarkat V
A real-world study of US patients with metastatic ovarian, fallopian tube, and peritoneal cancer (mOFPC) using integrated electronic health records (EHR) and claims datasets
Authors: B AP, Funingana G, Singh N, George R, Sowa A, Chakkrapani S, Priya V, Vaidya VP, Vidal L, Saini KS, Agrawal S
Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer
Authors: Naidoo J, Johnson DB, Doran C, Wang Y, Zhang Y, Le TK, Hopson S, Dreyfus B, Lal LS, Vyas C, Goldstein S, Izadi Z
Unfavorable early-stage Hodgkin lymphoma: assessment of patient characteristics in a real-world setting
Authors: Gautam S, Yeola S, Nahar A, Sarpong EM, Prescott J, Yang X, Sineshaw HM
Patient profiles, treatment patterns, and outcomes among persistent, recurrent, or metastatic cervical cancer patients under routine care in the United States
Authors: Gokhale M, Yu R, Monberg M, Tekin C, Chen L, DeClue RW, Knapp K, Lal LS
Treatment patterns and outcomes among locally advanced cervical cancer patients receiving concurrent chemoradiotherapy
Authors: Coutinho F, Gokhale M, Doran C, Monberg M, Yamada KS, Chen L
Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets
Authors: McKelvey BA, Garrett-Mayer E, Belli AJ, Brown TD, Dow J, Espirito JL, Kluetz P, Ma X, McCracken A, Mishra-Kalyani PS, Natanzon Y, Potter D, Rivera D, ...
Comparison of advanced ovarian cancer patients treated with or without bevacizumab in the US community oncology clinics
Authors: DeClue RW, Szamreta EA, Gautam S, Fisher MD, Monberg MJ
Real-world management and outcomes for newly diagnosed AML patients initiating Venetoclax and hypomethylating agents in US community practice
Authors: McNeill AM, Wang Y, Doran C, Cain LE, Liu Y, Lan Z, Pullarkat V
Treatment outcomes in patients (pts) with advanced/metastatic non‑small cell lung cancer (NSCLC) harboring MET amplification as a secondary oncogenic driver
Authors: Ryder A, Oksen D, Boutmy E, Ellers-Lenz B, Stroh C, Karachaliou N
Biomarker testing and treatment patterns in US patients (pts) with advanced/metastatic non‑small cell lung cancer (NSCLC) harboring MET amplification
Authors: Ryder A, Oksen D, Boutmy E, Wang Y, Nisbett AR, Stroh C, Johne A
CO210 Real-World Effectiveness and Treatment Patterns of Venetoclax-Based Regimens Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated in Community Settings
Authors: Zakeri M, Emechebe N, Chowdhery R, Jawaid D, Alhasani H, Manzoor BS
Real-world study on characteristics, post-nephrectomy journey, and outcomes of patients with early-stage renal cell carcinoma based on risk groups
Authors: Karam JA, Bhattacharya R, Ogbomo A, Gautam S, Yu R, Sundaram M, Imai K, Chhabra J, Haas NB
Evaluating clinical trial inclusion/exclusion criteria from claims using generative artificial intelligence
Authors: Mueller J, Parikh RB, Noble A
Electronic health record (EHR) and genomics-based machine learning (ML) to predict therapeutic effectiveness among patients with hormone-receptor positive (HR)+/HER2- advanced breast cancer (aBC)
Authors: Hathi DK, Pisano S, Honarvar H, Parikh RB, Das RK
Risk of Death Before and After Metastasis in High-Risk Localized and Locally Advanced Prostate Cancer Patients Undergoing Radical Prostatectomy or Radiotherapy as Primary Treatment in the United States: A Retrospective Study
Authors: Freedland S, Fernandes L, De Solda F, Buyukkaramikli N, Labson D, Yang L, Pan F, Mir MC
Assessment of electronic health record (EHR) –based machine learning (ML) in predicting risk of brain metastasis among patients with early-stage non–small-cell lung cancer (eNSCLC)
Authors: Honarvar H, Hathi DK, Parikh RB, Das RK
Identification of biomarkers for early progression in muscle invasive bladder cancer (MIBC) using real-world data
Authors: Singh N, George R, Agrawal S
Digital trial solutions eScreening: software to rank patients by their predicted clinical trial eligibility using real-world data and machine learning
Authors: Bhandari S, Levonian Z, Annand R, Baxter J-Z, Cain J, Flach J, Joseph-Thomas J, Mueller J
A machine learning model to facilitate patient-level risk screening in myelodysplastic syndromes (MDS) patients in routine clinical practice
Authors: Vaidya V, Vaidya V, Priya V, Parmar D, Yan R, Das R, Haririfar M, McMahon P, Williamson M, Hogea C
Electronic health record (EHR)-based machine learning (ML) to predict disease recurrence after surgical resection of early-stage non-small cell lung cancer (eNSCLC)
Authors: Pisano S, Honarvar H, Parikh RB, Das RK
Real-world treatment patterns and clinical outcomes post standard of care (SOC) among patients (pts) with metastatic non-small cell lung cancer (mNSCLC) with and without actionable genomic alterations (AGAs) in the United States (US)
Authors: Shah R, Kariburyo-Yay F, Apple J, Lal LS, Miller V, Kwong J, Reuss JE
LUMINATE 102: A real-world study on biomarker testing rates among patients with non-small cell lung cancer (NSCLC) across lines of therapy
Authors: Aggarwal C, Xu Q, Ng S, Kamalakar R, Crawford S, Beruti S, Myftiu A, Beasley MB
PP01.46 Real-world rebiopsy and biomarker retesting rates among patients with non-small cell lung cancer across patient demographics in the United States
Authors: Aggarwal C, Xu Q, Ng S, Kamalakar R, Crawford S, Beruti S, Myftiu A, Beasley MB
PP01.58 Real-world outcomes in patients with EGFR wildtype non-squamous locally advanced/metastatic NSCLC receiving second- or third-line docetaxel: Pooled analysis from LUMINATE-101
Authors: Girard N, Xu Q, Camidge DR, Baijal S, Karve S, Ng S, Kamalakar R, Ratajczak C, Allen A, Lu S
Augmenting synthetic control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer
Authors: Strübing A, McKibbon C, Ruan H, Mackay E, Dennis N, Velummailum R, He P, Tanaka Y, Xiong Y, Springford A, Rosenlund M
Evaluation of patients with multiple EGFR genomic tests in the metastatic NSCLC setting
Authors: Lal L, Williford AO, Milne DE, Walker MS
Evaluation of treatment strategies for patients with stage IIIA non-small cell lung cancer in the immunotherapy era
Authors: Alabaster A, Velotta JB, Tupper HI, Natanzon Y
Real-world treatment patterns and sequencing in patients with locally advanced or metastatic urothelial cancer (la/mUC) in the US
Authors: Kearney M, Mahmoudpour H, Ike C, Modh A, Monzon S, Fragkogianni M, Carson K
Disparities in genetic testing patterns and positivity among patients with breast cancer in the CancerLINQ real-world oncology database
Authors: Kantor O, Jones A, Bychkovsky B, Laws A, Weiss A, Rana H, Garber J, Scheib R, Chavez M, Mayer E, King T, Mittendorf E
Patient characteristics, treatment patterns, and factors of biomarker testing among patients with advanced non-small cell lung cancer (ANSCLC) in the US, 2012-2020
Authors: Yang M, MacEwan J, Honnold R, McClain MR, O'Hara R, Liu F, Paik P
Association of clinical trial enrollment and mortality amongst patients with advanced prostate cancer
Authors: Pessoa RR, Flaig T, Robin T, Gershman B, Bronsert M, Kiani K, Ballon-Landa E, Eule C, Kessler E, Smaldone MC, Kim SP
Variation of hormonal agent usage with postoperative radiation therapy: Results from a population based cohort of prostate cancer patients in community oncology practices
Authors: Pessoa RR, Robin T, Flaig T, Molina E, Gershman B, Ballon-Landa E, Eule C, Kessler E, Chapin B, Smaldone MC, Kim SP
Chasm between cancer quality measures and electronic health record data quality
Authors: Schorer AE, Moldwin R, Koskimaki J, Bernstam EV, Venepalli NK, Miller RS, Chen JL
Quantitating and assessing interoperability between electronic health records
Authors: Bernstam EV, Warner JL, Krauss JC, Ambinder E, Rubinstein WS, Komatsoulis G, Miller RS, Chen JL
Retrospective analysis of real-world management of EGFR-mutated advanced NSCLC, after first-line EGFR-TKI treatment: US treatment patterns, attrition, and survival data
Authors: Nieva J, Reckamp KL, Potter D, Taylor A, Sun P
Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 and Subsequent Mortality in a Multisite Cohort of Patients With Cancer in the CancerLinQ Discovery Database
Authors: Ray EM, Riffon MF, Kakamada S, Miller RS, Potter D
Cancer registry data linkage of electronic health record data from ASCO's CancerLinQ: Evaluation of advantages, limitations, and lessons learned
Authors: Charlton ME, Kahl AR, McDowell BD, Miller RS, Komatsoulis G, Koskimaki JE, Rivera DR, Cronin KA
Survival in the real world: A national analysis of patients treated for early-stage breast cancer
Authors: Gidwani R, Franks JA, Enogela EM, Caston NE, Williams CP, Aswani MS, Azuero A, Rocque GB
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
Authors: Thanarajasingam G, Minasian LM, Bhatnagar V, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gormley N, ...
Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study
Authors: Miller RS, Mokiou S, Taylor A, Sun P, Baria K
Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer
Authors: Hu X, Walker MS, Stepanski E, Kaplan CM, Martin MY, Vidal GA, Schwartzberg LS, Graetz I
Efficacy of lurbinectedin in a clinical trial versus standard of care in a real-world comparator arm in relapsed/refractory small cell lung cancer patients
Authors: Ganti AK, Prince P, Wang X, Estrin A, Boccuti A, Rengarajan B, Naveh N, D'Agostino Jr. R, Alvord T, Ben-Joseph R
Machine learning modeling of real-world primary resistance and hyperprogression in immune checkpoint inhibitor (ICI) treated advanced non-small cell lung cancer (aNSCLC) patients
Authors: Das RK, Hathi DK
Disparities in timely treatment among lung cancer patients
Authors: Chhabra J, Ray H, Derkach S, Thompson D, Whyte W
Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy
Authors: Minchom A, Viteri S, Bazhenova L, Gadgeel SM, Ou SHI, Trigo J, Bauml JM, Backenroth D, Bhattacharya A, Li T, Mahadevia P, Girard N
Real-world treatment patterns and outcomes of daratumumab retreatment in multiple myeloma in the United States
Authors: Girvan A, Yu J, Emechebe N, Kamalakar R, Luo Y
Treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma receiving ≥3 lines of therapy: A real-world evaluation in the United States
Authors: Girvan A, Yu J, Kamalakar R, Mearns ES, Nixon M, Cornell RF
Real-world outcomes among patients with metastatic colorectal cancer treated first line with bevacizumab-awwb
Authors: Jin R, Ogbomo AS, Accortt NA, Lal LS, Bishi G, Sandschafer D, Goldschmidt JH
STREAMLINE - Retrospective cohort study of FLT3-mutated acute myeloid leukemia (AML): Real-world treatment patterns and clinical outcomes after first relapse or refractory (R/R) diagnosis
Authors: Zeidan AM, Gautam S, Yu R, Lan Z, Grinblatt DL, ElSouda D, Spalding J, Block A, Touya M, Pandya BJ
Natural language processing-optimized case selection for real-world evidence studies
Authors: Koskimaki J, Hu J, Zhang Y, Mena J, Jones N, Lipschultz E, Vaidya VP, Altay G, Erese VA, Swaminathan KK, Mendonca E, Dutt T, Singh K, King T, ...
Real-world outcomes among HER2-positive metastatic breast cancer patients treated with trastuzumab deruxtecan in the United States
Authors: Kariburyo-Yay F, Mehta S, Kwong J, Lam C, Doran C, Lan Z
Unmet need in heavily pre-treated patients with HR+/HER2- metastatic breast cancer (mBC) in the US: a ConcertAI analysis
Authors: Waks AG, Gharaibeh M, Sjekloca N, Poluparthi N, Shah A, Bergamaco E, MacCannell T, Leung G, Ntalla I, Oko-osi H, Tolaney SM
Use of immunosuppressive drugs and the effectiveness of immune checkpoint inhibitor therapy among patients with advanced/metastatic non-small cell lung cancer in the United States
Authors: Dreyfus B, Zhang E, Doran C, Le K, Kola C, Sylvester BE, Punekar R, Lal L, Penrod J, Meadows-Shropshire SL
Outcomes among patients with mantle cell lymphoma post-covalent BTK inhibitor therapy in the United States: a real-world electronic medical records study
Authors: Hess LM, Chen Y, Abada PB, Konig H, Walgren RA
Outcomes for patients with mantle cell lymphoma post-covalent BTK inhibitor therapy in the United States and Japan: a study of two real-world databases
Authors: Rai S, Hess LM, Chen Y, Bowman L, Abada PB, Konig H, Walgren RA, Tanizawa Y, Cai Z, Tajimi M
Outcomes for patients with chronic lymphocytic leukemia (CLL) previously treated with both a covalent BTK and BCL2 inhibitor in the United States: A real-world database study
Authors: Mato AR, Hess LM, Chen Y, Abada PB, Konig H, Pagel JM, Walgren RA
Real-world patient profiles, treatment patterns, and outcomes among recurrent, persistent, and metastatic cervical cancer patients
Authors: Gokhale M, Yu R, Monberg M, Tekin C, Fan L, DeClue R, Knapp K, Lal LS
Early-stage unfavorable Hodgkin lymphoma: Patient characteristics in real-world oncology data from the United States
Authors: Gautam S, Yeola S, Nahar A, Sarpong EM, Prescott J, Yang X, Sineshaw HM
Treatment patterns and clinical outcomes among patients with relapsed/refractory classical Hodgkin's lymphoma
Authors: Nisbett AR, Yang X, Squires P, Gautam S, Desai K, Raut M, Nahar A
Disease-free and overall survival outcomes for localized RCC patients by disease stage
Authors: Haas NB, Bhattacharya R, Ogbomo AS, Imai K, Gautam S, Rogerio J, Yu R, Chhabra J, Sundaram M
Treatment patterns and outcomes among patients with EGFR-mutant advanced NSCLC in the frontline and post-osimertinib settings
Authors: Sabari J, Pisano S, Gemmler K, Mueller J, Bernabé Caro R, Girard N, Goto K, Leighl N, Ohe Y, Kim TM, Lee S-H, Demirdjian L, Rudolph S, Mahadevia P, ...
Lurbinectedin vs an external control arm in patients with small cell lung cancer
Authors: Ganti AK, Prince P, Wang X, Estrin A, Boccuti A, Rengarajan B, Naveh N, D'Agostino Jr. R, Alvord T, Ben-Joseph R
Disease-free survival (DFS) as a predictor of overall survival in completely reseacted early-stage non-small cell lung cancer (NSCLC)
Authors: West H, Hu X, Burke T, Walker MS, Wang Y, Samkari A
Treatment patterns, overall survival (OS), and disease-free survival (DFS) in early-stage non-small cell lung cancer (NSCLC) following complete resection
Authors: West H, Hu X, Burke T, Walker MS, Wang Y, Samkari A
Racial disparities in newly diagnosed hematological malignancies in the United States during the COVID-19 pandemic, January 2020 to March 2021
Authors: Bhandari S, Chawla J, Jain P, Kaushiva A, Lagor C, Lal L, Mueller J, Whyte W
Identifying genetic factors of response and resistance to CDK4/6 inhibitors in metastatic HR+/HER2-breast cancer using real-world data
Authors: Agrawal S, Singh N, Narayanan B
Impact of trial site selection on minority patient recruitment in prostate cancer trials
Authors: Lagor C, Bhandari S, Chawla J, Knight M, Mann J, Mueller J, Raska P, Southwick S, Whyte W
Effect of COVID-19 vaccination status on adverse events and outcomes in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapies
Authors: George R, Narayanan B, Agrawal S
Evaluating the impact of performance status criteria on minority eligibility for oncology clinical trials
Authors: Bhandari S, Mann J, Chawla J, Jain P, Knight M, Lagor C, Mueller J, Raska P, Southwick S, Whyte W
Comparison of DNA sequencing, immunohistochemistry, and in-situ hybridization techniques to determine HER2 status in metastatic breast cancer patients
Authors: Lal LS, Milne D, Walker MS, Kovach M
Cohort optimizer, a software solution that uses real-world data and AI to optimize criteria of oncology trials
Authors: Bhandari S, Mann J, Hajela R, Govil V, Greatti Y, Maguire R, Powers J, Southwick S, Mueller J
Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) after prior treatment (tx) with FUL in patients (pts) with advanced breast cancer (ABC): A real-world (RW) analysis
Authors: O'Shaughnessy J, Woeckel A, Pistilli B, Hegg R, Vahdat LT, Vuina D, Zadeh PA, Smith TW, Kim J, Krop I
Identifying genetic factors for resistance and response to immune checkpoint inhibitors (ICIS) in advanced non-small cell lung cancer (aNSCLC) patients using real-world data
Authors: Singh NK, Agrawal S, Narayanan B
Race differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer
Authors: Hu X, Walker MS, Stepanski E, Kaplan C, Martin MY, Vidal GA, Schwartzberg LS, Graetz I
Treatment effectiveness in a rare oncology indication: Lessons from an external control cohort study
Authors: Oksen D, Prince P, Boutmy E, Garry EM, Ellers-Lenz B, Estrin A, Johne A, Verpillat P, Gatto NM
Associations between biomarker testing and characteristics of patients with metastatic non–small cell lung cancer (mNSCLC): An analysis of CancerLinQ Discovery (CLQD) data
Authors: Mileham KF, Garrett-Mayer E, Kaltenbaugh M, Kirkwood MK, Schenkel C, Bruinooge SS, Osarogiagbon RU, Jalal SI, Moore A, Roy UKB, Freeman-Daily J, ...
Molecular testing and patterns of treatment in NSCLC patients: An IASLC analysis of ASCO CancerLinQ Discovery data
Authors: Behera M, Joseph G, Rupji M, Huang Z, Bunn B, Wynes M, Switchenko JM, Scagliotti GV, Higgins KA, Tsao MS, Belani CP, Sequist LV, Ramalingam SS
The survival benefit of anti-HER2 treatment in the management of small (T1mic, T1a, T1b, T1c), node-negative HER2+ breast cancer
Authors: Johnson KCC, Ni A, Grimm M, Sardesai SD, Stover DG, Cherian MA, Gatti-Mays ME, Pariser A, Sudheendra PK, Williams NO, VanDeusen JB, Ramaswamy B, ...
Diagnosed with advanced prostate cancer: A population-based cohort from national oncology practices
Authors: Kim SP, Kiani K, Konety B, Bronsert M, Candelario N, Kessler ER, Gershman B, Tyler R, Flaig TW
Characterizing node-negative non-small cell lung cancer patients with similarity networks: A CancerLinQ Discovery analysis
Authors: Moen EL, Chen Z, Schaefer A, Bhimani A, O'Malley J, Dragnev KH
Long term survival outcomes in NSCLC patients with targeted therapy and immunotherapy: An IASLC analysis of ASCO CancerLinQ Discovery data
Authors: Behera M, Joseph G, Rupji M, Huang Z, Bunn B, Wynes M, Switchenko J, Scagliotti G, Higgins K, Tsao M, Belani C, Sequist L, Ramalingam SS
935P - Demographics, clinical characteristics, treatment patterns and clinical outcomes of patients with stages I-III resected NSCLC without known EGFR mutations
Authors: Altorki NK, Salmonsen R, Georgoulia NE, Perez ID, Wang A, Cai L, Wetherill G, Xiao Y, Fielden C, Gray JE
Real world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
Authors: Sukumar JS, Sardesai S, Ni A, Williams N, Ramaswamy B, Wesolowski R, Cherian MA, Stover D, Gatti-Mays M, Pariser AC, Sudheendra PK, George MA, ...
Secondary primary malignancies (SPMs) in adolescent and young adults (AYAs) with multiple myeloma (MM): An ASCO CancerLinQ analysis
Authors: Gibson SJ, Cooper JD, Thornton JA, Pham K, Sunderland K, DeStefano CB
Survival of patients with multiple myeloma diagnosed with second primary malignancies: An ASCO CancerLinQ analysis
Authors: Cooper JD, Thornton JA, Gibson SJ, Pham K, Sunderland K, DeStefano CB
Summary of the 12 most common cancers in the CancerLinQ Discovery (CLQD) database
Authors: Potter DM, Riffon MF, Manning B, Taylor A, Emmas C, Kabadi S, Jiang M, Miller RS
Challenges and opportunities to developing a frailty index using electronic health record data
Authors: Levit LA, Kaltenbaugh MW, Magnuson A, Hershman DL, Goncalves PH, Garrett-Mayer E, Bruinooge SS, Miller RS, Klepin HD
Utilizing data visualization to identify survival and treatment differences between women with de novo and recurrent metastatic breast cancer
Authors: Gilbert A, Williams C, Azuero A, Burkard ME, Kenzik K, Garrett-Mayer E, Meersman S, Rocque G
Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer
Authors: Rhodes W, DeClue RW, Accortt NA, Jin R, Sandschafer D, Wertz D, Patel K
Demographics and clinical characteristics of metastatic colorectal cancer patients treated with bevacizumab-awwb in real-world oncology clinics
Authors: DeClue RW, Rhodes W, Accortt NA, Jin R, Sandschafer D, Wertz D, Patel K
Identification of transgender people with cancer in electronic health records: recommendations based on CancerLinQ observations
Authors: Alpert AB, Komatsoulis GA, Meersman SC, Garrett-Mayer E, Bruinooge SS, Miller RS, Potter D, Koronkowski B, Stepanski E, Dizon DS
Impact of broadening trial eligibility criteria for patients with advanced non–small cell lung cancer: real-world analysis of select ASCO-Friends recommendations
Authors: Harvey RD, Bruinooge SS, Chen L, Garrett-Mayer E, Rhodes W, Stepanski E, Uldrick TS, Ison G, Khozin S, Rubinstein WS, Schenkel C, Miller RS, ...
Real-world progression-free survival by timing of molecular profiling testing among metastatic non-small cell lung cancer patients in a community setting
Authors: Liu S, DeClue R, Nisbett A, Gautam S, Fisher MD, Shenolikar R
Demographics, clinical characteristics, and treatment patterns for patients with BRCA mutated, HER2-negative early stage breast cancer: a CancerLinQ® real-world US study
Authors: Mokiou S, DeClue RW, Gautam S, Herms L, Jiang M, Sun P, McCutcheon S, Stearns V, Nunes MR
Mild or moderate adverse events (AEs) and their management in patients receiving immune checkpoint inhibitors (ICIs) for advanced/metastatic non-small cell lung cancer (NSCLC) in the United States (US)
Authors: Punekar RS, Zhang Y, Le K, Dreyfus B, Kola N, Sylvester B
Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: A machine learning approach
Authors: Heilbroner SP, Few R, Neilan TG, Mueller J, Chalwa J, Charest F, Suryadevara S, Kratt C, Gomez-Caminero A, Dreyfus B
Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer
Authors: Zhang X, DeClue RW, Herms L, Yang M, Pawar V, Masters ET, Ruisi M, Chin K, Velcheti V
The Friends of Cancer Research real world data (RWD) collaboration pilot 2.0: Methodological recommendations from oncology case studies
Authors: Rivera DR, Henk HJ, Garrett-Mayer E, Christian JB, Belli AJ, Bruinooge SS, Espirito JL, Sweetnam C, Izano MA, Natanzon Y, Robert NJ, Walker MS, Cohen ...
Real-world overall survival using oncology electronic health record data: Friends of Cancer Research pilot
Authors: Lasiter L, Tymejczyk O, Garrett-Mayer E, Baxi S, Belli AJ, Boyd M, Christian JB, Cohen AB, Espirito JL, Hansen E, Sweetnam C, Robert NJ, Small M, ...
The Friends of Cancer Research Real World Data (RWD) Pilot 2.0 Collaboration: Implementation of Standardized Methodological Approaches for Evaluation of Oncology RWD
Authors: Rivera D, Henk H, Garrett-Mayer E, Walker MS, Wagner J, Valice E, Sweetnam C, Sharon E, Sakoda LC, Robert NJ, Benito RP, Natanzon Y, Kushi L, Izano ...
Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6i for HR+, HER2- MBC in the real world
Authors: Kalinsky K, Kruse M, Nash Smyth E, Guimaraes CM, Gautam S, Nisbett AR, Fisher MD, Cui ZL, Bowman L
Outcomes for patients with chronic lymphocytic leukemia previously treated with a covalent BTK inhibitor and BCL2 inhibitor in the United States: a real-world database study
Authors: Mato AR, Chen Y, Girvan AC, Hess LM, Bowman L, Abada PB, Konig H, Walgren RA
Outcomes for patients with mantle cell lymphoma post-covalent BTK inhibitor therapy in the United States and Japan: a study of two real-world databases
Authors: Rai S, Hess LM, Chen Y, Bowman L, Abada PB, Konig H, Walgren RA, Tanizawa Y, Cai Z, Tajimi M
Healthcare Resource Utilization and Cost Among Patients Treated for Early-Stage Triple-Negative Breast Cancer
Authors: Haiderali A, Rhodes WC, Gautam S, Huang M, Sieluk J, Skinner KE, Schwartzberg LS
Real-World Treatment Patterns and Effectiveness Outcomes in Patients with Early-Stage Triple-Negative Breast Cancer
Authors: Haiderali A, Rhodes WC, Gautam S, Huang M, Sieluk J, Skinner KE, Schwartzberg LS
Clinical and utilization outcomes associated with tumor mutational burden in a real-world pan-tumor population
Authors: Gautam S, Kachroo S, DeClue RW, Fisher MD, Basu A
Demographic and clinical characteristics of advanced ovarian cancer patients treated with bevacizumab in real-world oncology clinics in the United States
Authors: DeClue RW, Szamreta EA, Gautam S, Fisher MD, Monberg MJ
Real-world patterns on tumor mutation burden testing in a pan-tumor population
Authors: Gautam S, Kachroo S, DeClue RW, Fisher MD, Basu A
Non-interventional cohort study on patients with advanced non-small cell lung cancer harboring MET exon 14 skipping in the US
Authors: Ryder A, Oksen D, Vlahiotis A, Boutmy E, Dietz LA, Stroh C, Johne A, Walker M
Enhancing diversity in oncology clinical trials: Findings of a case study in improving black patient representation in a multiple myeloma trial
Authors: Bhandari S, Lagor C, Mueller J, Whyte W, Heilbroner
Assessment of differences in demographic characteristics and clinical diagnoses among black and white oncology patients with COVID
Authors: Bhandari S, Mueller J, Whyte W, Heilbroner SP
Machine learning imputation of metastatic status from open claims in melanoma patients
Authors: Vaidya VP, Prajapati R, Manirevu SV, George R, Agrawal S, Narayanan B
Algorithm to derive progression based lines of therapy from a real world non-small cell lung cancer (NSCLC) dataset
Authors: Agrawal S, Priya V, George R, Manirevu SV, Bhardwaj T, Prajapati R, Chakkrapani S, Walker MS, Vaidya VP, Narayanan B
Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer in community oncology settings
Authors: George DJ, Agarwal N, Rider JR, Li B, Shirali R, Sandin R, Hong A, Russell D, Ramaswamy K, Freedland SJ
Trends in biomarker testing among advanced NSCLC patients in oncology practice settings in the US
Authors: Levin R, Sullivan A, Li B, Shetty V, Krulewicz S, Bartolome [Pfizer team used our NSCLC Patient360 product to conduct the research themselves]
Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings
Authors: George DJ, Agarwal N, Rider JR, Li B, Shirali R, Sandin R, Hong A, Russell D, Ramaswamy K, Freedland SJ
Real-world effectiveness of EGFR TKI first-line treatment of advanced EGFR mutation-positive non-small cell lung cancer in the US
Authors: Gautam S, Herms L, Bartolome L, Pastel M, Wilner KD, Fisher MD, Ivanova JI
Treatment patterns and overall survival in HER2+ metastatic breast cancer at US community oncology practices
Authors: Vidal GA, Gautam S, Vlahiotis A, Fisher MD, Pulgar S, DeBusk K
Characterization of clinical symptoms by race among women with early stage, hormone receptor-positive breast cancer before starting chemotherapy
Authors: Hu X, Chehal PK, Kaplan C, Krukowski R, Lan RH, Stepanski E, Schwartzberg L, Vidal G, Graetz I
Differences by race in patient-reported symptoms during chemotherapy among women with early-stage, hormone receptor-positive breast cancer
Authors: Hu X, Kaplan C, Stepanski E, Schwartzberg LS, Vidal GA, Walker MS, Martin MY, Graetz I
Treatment patterns and outcomes of hepatocellular carcinoma (HCC) patients (pts) in the CancerLinQ Research Database (CLQ)
Authors: Kabadi S, Luo L, Moren A, Baria K
Care at the end of life during the COVID-19 pandemic: A CancerLinQ Discovery® (CLQD) Analysis
Authors: Rocque GB, Riffon M, Paskett ED, Jazieh AR, King JC, Potter DM
Development of a breast cancer-specific prognostic tool using CancerLinQ Discovery
Authors: Ray EM, Zhang X, Dunham L, Tan X, Lafata JE, Reeder-Hayes KE
Survival in the real world: A national analysis of patients treated for early stage breast cancer
Authors: Franks J, Gidwani R, Enogela EM, Caston NE, Williams C, Aswani MS, Azuero A, Rocque GB
Natural history and real-world treatment outcomes for NSCLC patients with EGFR exon 20 insertion mutation: An IASLC- ASCO CancerLinQ study
Authors: Behera M, Jiang R, Huang Z, Bunn B, Wynes M, Switchenko J, Scagliotti G, Belani C, Ramalingam S
Treatment patterns and characteristics in the second and third-line therapy setting for real-world small cell lung cancer patients
Authors: Prince P, Estrin A, Supina D, Ben-Joseph R, Boccuti A, Asubonteng K, Rengarajan B, Fridman M, Hanvesakul R, Taylor B
Overall survival throughout treatment course among patients diagnosed with small cell lung cancer
Authors: Estrin A, Prince P, Supina D, Ben-Joseph R, Boccuti A, Asubonteng K, Fridman M, Rengarajan B, Hanvesakul R, Taylor B
Disruptions to US medical oncology care during the COVID-19 pandemic: CancerLinQ Discovery® (CLQD) analysis
Authors: Jazieh AR, Riffon M, King JC, Rocque GB, Paskett ED, Potter DM
773 - Evaluating clinical features and prognostic factors associated with response to immune checkpoint blockade in mNSCLC patients
Authors: Jain P, Stein M, Gao Y, Lau D, Khan AA
66P - EGFR testing patterns and survival in stage I‒III non-small cell lung cancer (NSCLC): analysis using the CancerLinQ Discovery® (CLQD) database
Authors: Potter D, Sun P, Li J, Luo L, Taylor A
Retrospective electronic health records study in the CancerLinQ Discovery database of treatment patterns among patients with chronic lymphocytic leukemia
Authors: Kabadi S, Kumar S
Improving cancer data interoperability: The promise of the minimal Common Oncology Data Elements (mCODE) initiative
Authors: Osterman TJ, Terry M, Miller RS
Development of CancerLinQ, a health information learning platform from multiple electronic health record systems to support improved quality of care
Authors: Potter D, Brothers R, Kolacevski A, Koskimaki JE, McNutt A, Miller RS, Nagda J, Nair A, Rubinstein WS, Stewart AK, Trieb IJ, Komatsoulis GA
Metastatic colorectal cancer patients treated with a biosimilar to bevacizumab in real world clinical setting
Authors: Rhodes W, Accortt N, DeClue R, Jin R, Sandschafer D, Wertz D, Patel K
Demographics and clinical characteristics of metastatic colorectal cancer patients treated with a biosimilar to bevacizumab
Authors: Rhodes W, Accortt N, DeClue R, Jin R, Sandschafer D, Wertz D, Patel K
Annual trends in opioid prescribing for patients with metastatic non-small cell lung cancer (mNSCLC): Cancerlinq data analysis, 2010 to 2017
Authors: Paice JA, Chen L, Garrett-Mayer E, Hagerty KS, Novick KLM, Potter D, Riffon M, Rhodes W, Wang L, Bruinooge SS
Identification of transgender people with cancer in electronic health records (EHR): Recommendations based on CancerLinQ observations
Authors: Alpert A, Bruinooge SS, Dizon DS, Koronkowski B, Garrett-Mayer E, Meersman SC, Miller RS, Potter D, Komatsoulis GA
Streamline – Retrospective cohort study of relapsed or refractory (R/R) FLT3 mutated acute myeloid leukemia (AML): Real-world treatment, testing patterns, and outcomes
Authors: Zeidan AM, Gilligan AM, Gautam S, Grinblatt DL, Elsouda D, Sullivan L, Pandya BJ
Machine learning imputation of Eastern Cooperative Oncology Group performance status (ECOG PS) scores from data in CancerLinQ discovery
Authors: Agrawal S, Narayanan B, Chandrashekaraiah P, Sai Vinod M, Nandi S, Vaidya V, Sun P, Cabrera C, Svensson D, Khosla S, Stepanski E, Komatsoulis GA
Artificial intelligence model to predict slow progression for advanced non-small cell lung cancer (aNSCLC) patients receiving second-line therapies
Authors: Charest F, Heilbroner SP, Rudeen K, Chawla J, Suryadevara S, Narayanan B
Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: A machine learning approach
Authors: Dreyfus B, Heilbroner SP, Few R, Kratt C, Gomez A
Cancer patient perspectives on sharing of medical records and mobile device data for research purposes
Authors: Franklin EF, Nichols HM, House L, Buzaglo J, Thiboldeaux K
Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC) patients: Analysis of real-world data
Authors: Kushi LH, Lasiter L, Belli AJ, Boyd M, Bruinooge SS, Christian J, Garrett-Mayer E, Hansen E, Honnold R, Benito RP, Natanzon Y, Sakoda L, Rivera DR, ...
Development of a prognostic factor index among women with HR+/HER2- metastatic breast cancer in a community oncology setting
Authors: Vidal GA, Cuyun Carter G, Gilligan AM, Saverno K, Zhu YE, Price GL, DeLuca A, Smyth EN, Rybowski S, Huang YJ, Schwartzberg LS
Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States
Authors: Aggarwal H, Punekar RS, Li L, Carter GC, Walker MS
Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer
Authors: Skinner KE, Haiderali A, Huang M, Schwartzberg LS
Clinical effectiveness outcomes and healthcare resource utilization of patients diagnosed with small cell lung cancer
Authors: Lin J, Gautam S, Hu N, Adeboyeje G, Kachroo S
Locoregional recurrence in patients with early-stage triple-negative breast cancer receiving neoadjuvant systemic therapy: Patient characteristics and clinical outcomes
Authors: Haiderali A, Rhodes WC, Gautam S, Huang M, Sieluk J, Skinner KE, Schwartzberg LS
Real-world conditional survival analysis of patients with relapsed/refractory classical Hodgkin’s lymphoma in the US
Authors: Desai KD, Yang X, Gilligan AM, Li Y, Raut M, Nahar A
Tumor mutational burden (TMB) level and clinical outcomes in a real-world pan-tumor population
Authors: Gautam S, Kachroo S, DeClue RW, Fisher MD, Basu A
Treatment patterns and effectiveness outcomes in patients with relapsed/refractory classical Hodgkin’s lymphoma that received autologous and/or allogenic stem cell transplantation
Authors: Iqbal S, Raut M, Gilligan AM, Clarke N, Sen S, Desai K, Yang X, Nahar A
Progression-free survival, overall survival, and tumor response for patients diagnosed with small cell lung cancer who received first-line systemic therapy
Authors: Lin J, Gautam S, Hu N, Wertz D, Adeboyeje G, Kachroo S
Assessing direct costs of treating metastatic triple-negative breast cancer in the USA
Authors: Skinner KE, Haiderali A, Huang M, Schwartzberg LS
Cost and healthcare resource utilization (HCRU) for patients receiving neoadjuvant therapy for early-stage triple-negative breast cancer (ESTNBC)
Authors: Rhodes WC, Gautam S, Haiderali A, Huang M, Sieluk J, Skinner KE, Schwartzberg LS
Healthcare resource utilization and cost in patients with relapsed/refractory classical Hodgkin’s lymphoma who received autologous stem cell transplantation in the US
Authors: Yang X, Desai KD, Gilligan AM, Raut M, Nahar A
Real-world evidence on use of tumor mutation burden in a pan-tumor population.
Authors: Gautam S, Kachroo S, DeClue RW, Fisher MD, Basu A
Treatment patterns, healthcare resource utilization and cost among relapsed/refractory classical Hodgkin’s lymphoma patients in the US
Authors: Yang X, Desai K, Gilligan AM, Clarke N, Raut M, Sen S, Nahar A
Treatment patterns, healthcare resource utilization and patient-reported outcomes for patients diagnosed with small cell lung cancer
Authors: Lin J, Gautam S, Hu N, Wertz D, Adeboyeje G, Kachroo S
Development of an artificial intelligence model to dynamically predict metastatic recurrence of early-stage breast cancer patients
Authors: Vaidya VP, Agrawal S, Sai Vinod M, Nagdewani S, Chandrashekaraiah P, Bhardwaj T, Narayanan B
Development of an algorithm using natural language processing to identify metastatic breast cancer patients from clinical notes
Authors: Swaminathan KK, Mendonca E, Mukherjee P, Thirumalai K, Newsome R, Narayanan B
Identifying non-small cell lung cancer patients from a cohort of heterogeneous lung cancer patients using boosted trees on electronic health records data
Authors: Chandrashekaraiah P, Rudeen K, Agrawal S, Thiruvenkadam S, Vaidya VP, Narayanan B
Racial disparities in performance status among cancer patients at a community oncology practice
Authors: Buzaglo JS, Musallam A, Stepanski E, Joiner M, Vanderwalde AM, Decker V
Using an ePRO tool to help meet quality metric reporting standards: screening for tobacco usage and falls
Authors: Buzaglo JS, Stepanski E, Joiner M, Taylor D, Musallam A, Richey SS, Schwartzberg LS, Vanderwalde AM, Decker VB
Performance of time to discontinuation and time to next treatment as proxy measures compared with direct observation of progression-free survival
Authors: Walker MS, Herms L, Miller PJE
Performance of time to discontinuation and time to next treatment as proxy measures of progression-free survival, overall and by treatment group
Authors: Walker MS, Herms L, Miller PJE
Treatment patterns and clinical outcomes with palbociclib-based therapy received in US community oncology practices
Authors: Lin J, McRoy L, Fisher MD, Hu N, Davis C, Mitra D, Walker MS
Patient and provider characteristics associated with first-line treatment of HR+/HER2- metastatic breast cancer patients in the US
Authors: Lin J, Lagor C, Nagdewani S, Few R, Mitra D
Occurrence of brain metastasis and treatment patterns among patients with HER2-positive metastatic breast cancer
Authors: Vidal GA, Pulgar S, Gautam S, Vlahiotis A, Fisher MD, DeBusk K
Vital status ascertainment in cancerlinq discovery (CLQD): Improvement in mortality capture with a supplemental data source
Authors: Potter D, Kaltenbaugh M, Kabadi S, Taylor A, Pascual E, Koskimaki J, Brothers R, Stoeber P, Mena J, Garrett-Mayer E
Overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) patients treated with frontline chemotherapy or immunotherapy by comorbidity: A real-world data (RWD) collaboration
Authors: Rivera DR, Lasiter L, Christian J, Enewold L, Espirito JL, Hansen E, Henk HJ, Kushi LH, Lane D, Natanzon Y, Pe Benito R, Rasmussen E, Robert NJ, ...
Treatment trends with immune checkpoint inhibitor (ICI) therapy in older adults with lung cancer
Authors: Walko CM, Dickey A, Motsinger-Reif AA, Scholl E, McLeod HL, Hauser RS, Van Londen GJ, Singh H, Simon J
Low rates of BRCA1 and BRCA2 testing for patients with ovarian cancer in ASCO's CancerLinQ, a real-world database
Authors: Dewdney S, Potter D, Haidle JL, Hulick PJ, Riffon M, Monzon FA, Keole SR, Miller RS
The relationship between treatment intensity and characteristics of patients with early stage breast cancer
Authors: Franks J, Caston N, Williams C, Azuero A, Aswani MS, Gidwani R, Rocque GB
Impact of curated data on electronic quality measure capture rates within CancerLinQ
Authors: Rios KC, Thakkalapally A, Koskimaki J, Riffon M, Miller RS, Komatsoulis GA, Potter D
Disproportionate impact of COVID-19 disease among racial and ethnic minorities in the U.S. cancer population as seen in CancerLinQ Discovery data
Authors: Potter D, Riffon M, Kakamada S, Miller RS, Komatsoulis GA
Real-world clinical outcomes of patients with BRCA-mutated (BRCAm) HER2-negative metastatic breast cancer: A CancerLinQ® study
Authors: Miller RS, Mokiou S, Taylor A, Jiang M, Sun P, McCutcheon S
Retrospective electronic medical records study of treatment patterns among CLL patients in the CancerLinQ research database
Authors: Kabadi SM, Kumar SR, Wong JL
Real-world characteristics and outcomes of patients with advanced non-small cell lung cancer (aNSCLC) receiving immune checkpoint inhibitor
Authors: Khozin S, Zhi J, Jun M, Chen L, Rubinstein WS, Walker MS, Komatsoulis GA, Roberts J, Fukushima R, Lau D, Hyde B, Stepanski E, Miller RS
Characteristics of patients receiving immune checkpoint inhibitors (ICI) in ASCO’s CancerLinQ
Authors: Rubinstein WS, Chen L, Komatsoulis GA, Stepanski E, Jun M, Zhi J, Lau D, Roberts J, Miller RS, Walker MS, Fukushima R, Hyde B, Khozin S
Real-world prevalence of autoimmune disease (AD) among patients (pts) receiving immune checkpoint inhibitors (ICI) in ASCO’s CancerLinQ database
Authors: Chen L, Walker MS, Zhi J, Komatsoulis GA, Jun M, Stepanski E, Fukushima R, Lau D, Roberts J, Hyde B, Miller RS, Khozin S, Rubinstein WS
Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs)
Authors: Khozin S, Walker MS, Jun M, Chen L, Stepanski E, Rubinstein WS, Komatsoulis GA, Roberts J, Zhi J, Miller RS, Fukushima R, Lau D, Hyde B
Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis
Authors: Harvey RD, Rubinstein WS, Ison G, Khozin S, Chen L, Miller RS, Jun M, Stepanski E, Hyde B, Uldrick TS, Komatsoulis GA, Roberts J, Garrett-Mayer E, ...
Streamline - study of relapse or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) using electronic medical records (EMR): first analysis from a multicenter, retrospective cohort study
Authors: Zeidan AM, Gilligan A, Gautam S, Hu N, Grinblatt DL, Pandya BJ
Real-world effectiveness of fulvestrant monotherapy as first endocrine treatment in patients with metastatic breast cancer
Authors: Skinner KE, Olufade T, Walker MS, Schwartzberg LS
Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings
Authors: Houts AC, Olufade T, Shenolikar R, Walker MS, Schwartzberg LS
Real-world outcomes in patients with unresected stage III non-small cell lung cancer
Authors: Ryan KJ, Skinner KE, Fernandes AW, Punekar RS, Pavilack M, Walker MS, VanderWalde NA
Real-world treatment patterns among patients with unresected stage III non-small cell lung cancer
Authors: Ryan KJ, Skinner KE, Fernandes AW, Punekar RS, Pavilack M, Walker MS, VanderWalde NA
Treatment patterns and outcomes in patients with KRAS wild-type metastatic colorectal cancer treated in first line with bevacizumab- or cetuximab-containing regimens
Authors: Houts AC, Ogale S, Sommer N, Satram-Hoang S, Walker MS
Progression-free survival in patients receiving chemotherapy alone (C) or chemotherapy with bevacizumab (CB) for first-line treatment of KRAS mutant metastatic colorectal cancer in community oncology settings
Authors: Houts AC, Ogale S, Zafar Y, Hubbard JM, Satram-Hoang S, Sommer N, Walker MS
Real-world outcomes in patients receiving neoadjuvant chemotherapy for early-stage triple-negative breast cancer
Authors: Rhodes WC, Gautam S, Haiderali A, Huang M, Sieluk J, Skinner KE, Schwartzberg LS
Patient characteristics and real-world treatment patterns in patients with early-stage triple-negative breast cancer receiving neoadjuvant chemotherapy
Authors: Rhodes WC, Gautam S, Haiderali A, Huang M, Sieluk J, Skinner KE, Schwartzberg LS
Using artificial intelligence to improve capture of metastatic breast cancer (BC) status in electronic health records (EHR)
Authors: Agrawal S, Colano V, Chandrashekaraiah P, Vaidya VP, Charest F, Manirevu SVK, Inbar O, Jun MP, Stepanski EJ, Walker MS, Peevyhouse A, Narayanan B, ...
Development of an artificial intelligence model to predict survival at specific time intervals for lung cancer patients
Authors: Agrawal S, Vaidya V, Chandrashekaraiah P, Kulkarni H, Chen L, Rudeen K, Narayanan B, Inbar O, Hyde B
Capturing patient advance directives status in a community oncology practice using an electronic patient-reported outcomes (ePRO) system
Authors: Buzaglo J, Skinner KE, Stepanski EJ, Decker V, Schwartzberg LS
Using an ePRO tool to help meet quality metrics in a community oncology practice
Authors: Buzaglo JS, Stepanski E, Joiner M, Taylor D, Tankersley C, Vanderwalde A, Schwartzberg LS
THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer
Authors: Paladino AJ, Anderson JN, Krukowski RA, Waters T, Kocak M, Graff C, Blue R, Jones TN, Buzaglo J, Vidal G, Schwartzberg L, Graetz I
A qualitative exploration of race-based differences in social support needs of diverse women with breast cancer on adjuvant therapy
Authors: Paladino AJ, Anderson JN, Graff JC, Krukowski RA, Blue R, Jones TN, Buzaglo J, Kocak M, Vidal GA, Graetz I
Effect of pegfilgrastim on-body injector (OBI) on cancer care: A real-world health system and interrupted time series analysis
Authors: Lin J, Yucel A, Walker MS, Perrin N, Bowers C, Fisher MD, Bensink M, Schwartzberg LS
Clinical outcomes among patients with unresected stage III non-small cell lung cancer (NSCLC) in a real-world setting
Authors: Ryan KJ, Punekar RS, Fernandes AW, Skinner KE, Pavilack M, Walker MS, Vergara-Silva A, VanderWalde NA
Effectiveness outcomes in patients with recurrent or refractory head and neck cancers: retrospective analysis of data from a community oncology database
Authors: Fisher MD, Fernandes AW, Olufade TO, Miller PJ, Walker MS, Fenton M
Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study
Authors: Skinner KE, Fernandes AW, Walker MS, Pavilack M, VanderWalde A
Patient characteristics and costs in recurrent or refractory head and neck cancer: retrospective analysis of a community oncology database
Authors: Fisher MD, Fernandes AW, Olufade TO, Miller PJ, Walker MS, Fenton M
Understanding health-related quality of life (HRQoL) in unresected stage III non-small cell lung cancer (NSCLC)
Authors: Ryan KJ, Skinner KE, Fernandes AW, Walker MS, Pavilack M, Punekar RS, VanderWalde NA
Real-world treatment patterns among patients with unresected stage III non-small cell lung cancer (NSCLC)
Authors: Punekar RS, Ryan KJ, Fernandes AW, Skinner KE, Pavilack M, Walker MS, Vergara-Silva A, VanderWalde NA
Pretreatment costs of care and time to initial treatment for patients with cancer of unknown primary
Authors: Walker MS, Weinstein L, Luo R, Marino I
Impacts of time spent on rituximab infusion on patient satisfaction, stress, employment, and caregiver burden
Authors: Fisher MD, Wallick CJ, Miller PJ, Walker MS, Lash S, Dawson KL, Reyes CM
Time spent on rituximab infusion and its impact on patient and caregiver burden
Authors: Fisher MD, Wallick CJ, Miller PJ, Walker MS, Lash S, Dawson KL, Reyes CM
Effect of brain metastasis on patient-reported outcomes in advanced NSCLC treated in real-world community oncology settings
Authors: Walker MS, Wong W, Ravelo A, Miller PJE, Schwartzberg LS
Treatment outcomes in patients with metastatic neuroendocrine tumors: a retrospective analysis of a community oncology database
Authors: Fisher MD, Pulgar S, Kulke MH, Mirakhur B, Miller PJ, Walker MS, Schwartzberg LS
Outcomes among metastatic breast cancer patients with characteristics that confer a less favorable prognosis
Authors: Saverno K, Carter, GC, Dufour R, Price G, Li L, DeLuca A, Smyth EN, Battiato L, Gable J, Walker MS, Huang YJ, Hannas S, Schwartzberg LS
Progression-free survival and overall survival in advanced squamous cell carcinoma of head and neck (SCCHN): retrospective analysis of a community oncology database
Authors: Aggarwal H, Punekar RS, Li L, Carter GC, Chin S, Bryant K, Miller PJ, Walker MS
Real-world effectiveness outcomes by race in patients with metastatic triple negative breast cancer
Authors: Skinner KE, Dufour R, Haiderali A, Huang M, Schwartzberg LS
Assessing the real-world cost of care in patients with metastatic triple negative breast cancer (mTNBC) in the United States
Authors: Skinner KE, Dufour R, Haiderali A, Huang M, Schwartzberg LS
Artificial intelligence methods to predict chemotherapy-induced neutropenia in breast cancer patients
Authors: DeWan PA, Inbar O, Spina CS, Rudeen K, Lagor C, Walker M, Stepanski E, Nwankwo J, Hyde B
Patient-reported outcomes among those taking pazopanib for metastatic renal cell carcinoma (mRCC) in a community oncology setting
Authors: Fisher MD, Ghate SR, Miller PJ, Walker MS, Ferrusi IL, Agarwal N
Patient reported outcomes in metastatic renal cell carcinoma patients receiving pazopanib in a community oncology setting
Authors: Fisher MD, Ghate SR, Miller PJ, Walker MS, Ferrusi IL, Agarwal N
Real-world treatment patterns and clinical outcomes with palbociclib combination therapy received in US community oncology practices
Authors: Trocio J, Lin J, Fisher MD, Hu N, Davis C, McRoy L, Walker MS, Iyer S
Real-world treatment patterns and clinical outcomes stratified by age, in women with HR+/HER2- advanced/metastatic breast cancer receiving palbociclib combination therapy
Authors: Lin J, Trocio J, Fisher MD, Hu N, Davis C, McRoy L, Walker MS, Iyer S
Treatment patterns and outcomes in stage IV bladder cancer in a community oncology setting: 2008-2015
Authors: Fisher MD, Shenolikar R, Miller PJ, Fenton M, Walker MS
Real-world clinical outcomes in BRCA-positive metastatic breast cancer patients treated in the community oncology setting
Authors: Houts AC, Olufade T, Shenolikar R, Walker MS
Progression-free survival in advanced head and neck cancer: retrospective analysis of a community oncology database
Authors: Fisher MD, Fernandes AW, Olufade TO, Miller PJ, Walker MS, Fenton M
Health care cost in patients with advanced non-small cell lung cancer and disease progression on targeted treatment in a real-world setting
Authors: Skinner KE, Fernandes AW, Walker MS, Pavilack M, VanderWalde A
Health resource utilization and costs in BRCA-positive metastatic breast cancer patients treated in the community oncology setting
Authors: Olufade T, Houts AC, Shenolikar R, Walker MS
Characteristics of patients treated with fulvestrant as first hormonal therapy for metastatic breast cancer in a real world setting
Authors: Skinner KE, Olufade T, Di Santo N, Shenolikar R, Walker MS, Schwartzberg LS
Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study
Authors: Walker MS, Wong W, Ravelo A, Miller PJE, Schwartzberg LS
Analysis of the psychological impact of cancer-related symptoms on patients with non-small cell lung cancer
Authors: Walker MS, Pohl GM, Houts AC, Peltz G, Miller PJE, Schwartzberg LS, Stepanski EJ, Marciniak M
Maximizing the utility of real-world evidence: integration of structured electronic medical record (EMR) data, unstructured EMR data, and billing data for economics and outcomes research in oncology
Authors: Walker MS, Ravelo A, Schulman K, Saverno K
Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA
Authors: Ivanova JI, Saverno KR, Sung J, Duh MS, Zhao C, Cai S, Vekeman F, Peevyhouse A, Dhawan R, Fuchs CS
Treatment patterns and outcomes in metastatic bladder cancer in community oncology settings
Authors: Fisher MD, Shenolikar R, Miller PJ, Walker MS, Fenton M
Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer
Authors: Cleeland C, von Moos R, Walker MS, Wang Y, Gao J, Chavez-MacGregor M, Liede A, Arellano J, Balakumaran A, Qian Y
Patient characteristics and costs in advanced head and neck cancer: retrospective analysis of a community oncology database
Authors: Fisher MD, Fernandes AW, Miller PJ, Walker MS, Fenton M
Clinical and health economic burden of attempted primary cancer site identification in patients presenting with cancer of unknown primary
Authors: Luo R, Weinstein L, Walker M, Marino I
Effectiveness outcomes in patients with advanced NSCLC treated in real world community oncology settings: results from a prospective medical record registry study
Authors: Walker MS, Wong W, Ravelo A, Hazard S, Miller PJE, Schwartzberg LS
Treatment patterns and outcomes in patients with KRAS wild type metastatic colorectal cancer (WTMCRC) treated in first line with bevacizumab (B) or cetuximab (C) containing regimens
Authors: Houts AC, Ogale S, Walker MS, Sommer N
Impact of disease progression on patient reported outcomes in advanced NSCLC: evidence from patients treated in real world community oncology settings
Authors: Walker MS, Wong W, Ravelo A, Hazard S, Miller PJE, Schwartzberg LS
Effect of brain metastasis on patient reported outcomes in advanced NSCLC treated in real world community oncology settings
Authors: Walker MS, Wong W, Ravelo A, Miller PJE, Schwartzberg LS
Treatment outcomes in patients with metastatic neuroendocrine tumors: retrospective analysis of a community oncology database
Authors: Fisher MD, Pulgar S, Kulke MH, Pitmann-Lowenthal S, Cox D, Miller PJ, Walker MS, Schwartzberg LS
The impact of extended endocrine therapy on symptom burden and health-related quality of life in patients with early-stage breast cancer (ESBC)
Authors: Fisher MD, Schroeder BE, Miller PJE, Schnabel CA, Schwartzberg L, Walker MS
US burden of illness associated with adjuvant therapy for stage I-III melanoma
Authors: Houts AC, Ward MA, Oglesby A, Walker MS, Saverno K
Treatment patterns and health resource utilization among patients diagnosed with early stage resected non-small cell lung cancer at US community oncology practices
Authors: Buck PO, Saverno KR, Miller PJE, Arondekar B, Walker MS
Treatment patterns and outcomes in metastatic neuroendocrine tumors: results from a retrospective community oncology database
Authors: Fisher MD, Pulgar S, Kulke MH, Pitmann-Lowenthal S, Cox D, Miller PJ, Walker MS, Schwartzberg LS
Maximizing the utility of real world evidence: integration of structured EMR data, unstructured EMR data, and billing data for economics and outcomes research in oncology
Authors: Walker MS, Schulman K, Ravelo A, Saverno K
Real-world impact of treatment-induced peripheral neuropathy of patient-reported outcomes in patients with multiple myeloma in the United States
Authors: Walker MS, Cong Z, Knopf KB, Aggarwal S, Kerr J, Houts AC
Real-world impact of treatment-induced peripheral neuropathy of patient-reported outcomes in patients with multiple myeloma in the United States
Authors: Walker MS, Cong Z, Knopf KB, Aggarwal S, Kerr J, Houts AC
Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice
Authors: Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR
Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice
Authors: Walker MS, Reyes C, Kerr J, Satram-Hoang S, Stepanski EJ
Early treatment discontinuation and switching in first-line metastatic breast cancer: the role of patient reported symptom burden
Authors: Walker MS, Masaquel AS, Kerr J, Lalla D, Abidoye O, Houts AC, Schwartzberg LS
Treatment patterns and baseline characteristics of a prospective cohort of patients with advanced NSCLC treated in real world community oncology settings
Authors: Walker MS, Ravelo A, Miller PJE
Real-world treatment patterns and health resource utilization among patients diagnosed with early stage resected non-small cell lung cancer (NSCLC) at community oncology practices in the US
Authors: Buck PO, Walker MS, Saverno KR, Miller PJE, Arondekar B
Association of treatment induced peripheral neuropathy with treatment patterns and outcomes in patients with newly diagnosed multiple myeloma
Authors: Walker MS, Kerr J, Martin MG, Panjabi S, TG
Use of “Real world” data to describe adverse events for the treatment of metastatic renal cell carcinoma in routine clinical practice
Authors: Hirsch BR, Harrison MR, George DJ, Walker MS, Chen C, Korytowsky B, Stepanski E, Abernethy AP
Real-world outcomes in metastatic renal cell carcinoma: insights from a joint community-academic registry
Authors: Harrison MR, Hirsch BR, George DJ, Walker MS, Chen C, Korytowsky B, Stepanski EJ, Abernethy AP
Clinical trial subjects compared to patients treated in "real world" practice: generalizability of renal cell carcinoma trials
Authors: Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR
Treatment patterns and clinical effectiveness in metastatic castrate resistant prostate cancer after first-line docetaxel
Authors: Houts AC, Hennessy D, Walker MS, Nicacio L, Thompson S, Miller PJE, Somer B
Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer
Authors: Cleeland C, von Moos R, Walker M, Wang Y, Gao J, Liede A, Arellano J, Balakumaran A, Qian Y
Willingness to pay for preventing chemotherapy induced nausea and vomiting among patients with breast, lung, or colorectal cancer
Authors: Miller P, Balu S, Buchner D, Walker M, Stepanski E, Schwartzberg L
The association of skin rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting
Authors: Stepanski EJ, Reyes C, Walker MS, Hoang SS, Leon L, Wojtowicz-Praga S, Miller PJE, Houts AC, Schwartzberg LS
Early treatment discontinuation and switching in 1st line metastatic breast cancer: impact of symptom burden in a real world sample
Authors: Walker MS, Masaquel AS, Kerr J, Lalla D, Abidoye O, Schwartzberg LS
Real world symptom burden and early treatment discontinuation in 1st line metastatic breast cancer
Authors: Walker MS, Masaquel AS, Kerr J, Lalla D, Abidoye O, Ogbata O, Schwartzberg LS
Treatment patterns and clinical characteristics of patients with advanced basal cell carcinoma in the community oncology setting
Authors: Walker MS, Schwartzberg LS, Chen DM, Ramanan DD, Houts AC, Reyes C
Predicting risk of chemotherapy-induced side effects in patients with colon cancer with single-nucleotide polymorphism (SNP) Bayesian networks (BNs)
Authors: Sonis ST, Schwartzberg LS, Walker MS, Weidner SM, Alterovitz G
Use of a validated assessment tool demonstrates the frequency of patient-experienced, regimen-related side effects associated with the treatment of common solid tumors
Authors: Miles K, Weidner SM, Sonis ST, Walker M, Chandler J
Anemia-related costs and adverse event rates in cancer patients who do not respond to erythropoietin stimulating agents
Authors: Landsman-Blumberg P, Shi N, Varker H, Juneau P, Girvan A, Pohl G, Lau J, Bowman L
KRAS testing of mCRC patients in a community-based oncology setting
Authors: Carter GC, Landsman-Blumberg PB, Johnson BH, Sedgley R, Shankaran V
Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases
Authors: Walker MS, Miller PJE, Namjoshi M, Houts AC, Stepanski EJ, Schwartzberg LS
Association of treatment induced peripheral neuropathy (TIPN) with treatment patterns and outcomes in patients with newly diagnosed multiple myeloma
Authors: Martin TG, Panjabi S, Kerr J, Martin MG, Walker MS
Adverse events among patient treated for metastatic renal cell carcinoma (mRCC): data from a real world, multicenter registry
Authors: Hirsch BR, Harrison MR, Walker MS, Roe L, Chen C, Korytowsky B, Stepanski EJ, George DJ, Abernethy AP
Adverse events (AEs) by age: data from a real world, multicenter registry of patients treated for metastatic renal cell carcinoma (mRCC)
Authors: Harrison MR, Hirsch BR, Walker MS, Roe L, Chen C, Korytowsky B, Stepanski E, George DJ, Abernethy AP
“Real world” treatment of metastatic renal cell carcinoma in a joint community- academic cohort: progression-free survival over three lines of therapy
Authors: Harrison MR, George DJ, Walker MS, Chen C, Korytowsky B, Kirkendall DT, Stepanski EJ, Abernethy AP
Community oncology treatment patterns and clinical effectiveness in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed after docetaxel
Authors: Houts AC, Hennessy D, Walker MS, Nicacio L, Thompson S, Miller PJE, Somer B
Using text mining of electronic medical records to identify KRAS testing status in mCRC patients
Authors: Miller PJE, Walker MS, Landsman-Blumberg PB, Carter GC
Treatment patterns and outcomes in metastatic gastric cancer in the community oncology setting
Authors: Walker MS, Lalla D, Houts AC, Schwartzberg LS
Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer
Authors: Walker MS, Yu E, Kerr J, Yim YM, Stepanski EJ, Schwartzberg LS
Treatment patterns and clinical characteristics of patients with advanced basal cell carcinoma (aBCC) in the community oncology setting
Authors: Walker MS, Schwartzberg LS, Chen DM, Ramanan D
Outcomes of “real world” treatment for metastatic renal cell carcinoma (mRCC)
Authors: Harrison MR, George DJ, Walker MS, Hudson LL, Chen C, Korytowsky B, Stepanski E, Abernethy AP
Willingness to pay to prevent chemotherapy induced nausea and vomiting
Authors: Miller PJE, Balu S, Buchner D, Walker MS, Stepanski EJ, Schwartzberg LS
Cancer patient preferences and willingness to pay for preventing chemotherapy induced nausea and vomiting in the U.S.
Authors: Miller PJE, Balu S, Buchner D, Walker MS, Stepanski EJ, Schwartzberg LS
Symptom burden and quality of life in patients with follicular lymphoma undergoing maintenance treatment with rituximab compared with observation
Authors: Walker MS, Stepanski EJ, Reyes C, Satram-Hoang S, Houts AC, Schwartzberg LS
Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients
Authors: Walker MS, Hasan M, Yim YM, Yu E, Stepanski E, Schwartzberg L
Treatment patterns among patients with metastatic melanoma treated in the community oncology setting
Authors: Walker MS, Reyes C, Kerr J, Satram-Hoang S, Stepanski EJ
The Patient Care Monitor-Neutropenia Index: development, reliability, and validity of a measure for chemotherapy-induced neutropenia
Authors: Olsen JP, Baldwin S, Houts AC
“Real world” treatment of metastatic renal cell carcinoma (mRCC) in community and academic settings
Authors: George DJ, Walker MS, Hudson LL, Chen C, Korytowsky B, Harrison MR, Stepanski E, Abernethy AP
Symptom burden declines when breast cancer patients treated with adjuvant trastuzumab / combination chemotherapy regimens enter trastuzumab monotherapy follow-up
Authors: Houts A, Lalla D, Walker M, Stepanski E, Brammer M, Doan J, Schwartzberg L
Testing and treatment patterns in HER2+ breast cancer patients in the adjuvant setting
Authors: Lalla D, Stepanski EJ, Benn L, Brammer M, Solari PG, Walker MS, Schwartzberg; LS
Treatment patterns, medical resource use, and costs associated with second line treatment of non small cell lung cancer
Authors: Walker MS, Pohl GM, Peltz G, Stepanski EJ, Faries D, Marciniak MD, Schwartzberg LS
Engagement of lung cancer patients in quality of life assessments administered by tablet computer as a routine part of clinical care
Authors: Walker MS, Houts AC, Hasan M, Stepanski EJ, North S, Schwartzberg LS
Use of the Patient Care Monitor to screen for depression in adult cancer patients interviewed with the structured clinical interview for DSM-IV
Authors: Houts AC, Lipinski D, Olsen JP, Baldwin S, Hasan M
Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients
Authors: Abernethy AP, Zafar SY, Uronis H, Wheeler JL, Coan A, Rowe K, Shelby RA, Fowler R, Herndon JE, 2nd
A retrospective study of quality of life in a community sample of patients with early stage breast cancer
Authors: Walker MS, Schwartzberg LS, Stepanski EJ, Fortner BV
The effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients
Authors: Hasan M, Walker M, Yim YM, Yu E, Stepanski E, Schwartzberg L
Symptom burden in patients with follicular lymphoma undergoing maintenance treatment with Rituxan compared with observation
Authors: Walker M, Stepanski E, Reyes C, Hasan M, Schwartzberg L
Psychosocial impact of cancer related symptoms among patients with lung cancer
Authors: Walker M, Peltz G, Houts A, Pohl G, Schwartzberg L, Stepanski E, Marciniak M
The relation of trouble sleeping, depressed mood, pain and fatigue in patients with cancer
Authors: Stepanski EJ, Walker MS, Schwartzberg LS, Blakely LJ, Ong J, Houts AC
Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology
Authors: Abernethy AP, Herndon JE, 2nd, Wheeler JL, Day JM, Hood L, Patwardhan M, Shaw H, Lyerly HK
Considerations in the use of secondary data sources for oncology research
Authors: Schulman KL, Foley KA, Walker MS
Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer
Authors: Schwartzberg LS, Cobb P, Senecal F, Henry D, Kulig K, Walker MS, Houts AC, Stepanski EJ
Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: Assessment of clinical consequences
Authors: Schwartzberg LS, Stepanski EJ, Fortner BV, Houts AC
Relation of sleep disturbance, depression, pain, and fatigue in patients with cancer
Authors: Stepanski EJ, Walker MS, Schwartzberg LS, Blakely LJ
Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data
Authors: Abernethy AP, Herndon JE, 2nd, Wheeler JL, Patwardhan M, Shaw H, Lyerly HK, Weinfurt K
Irinotecan is associated with greater symptom burden than oxaliplatin in metastatic colorectal cancer patients (mCRC) in community oncology
Authors: De Moor C, Abernethy A, Sullivan P, Schwartzberg LS
Prevalence of insomnia and associated symptoms in patients with cancer
Authors: Stepanski EJ, Walker MS, Schwartzberg LS, Blakely LJ, Fu D, Fortner BV
Symptom burden for patients with metastatic colorectal cancer treated with first-line FOLFOX or FOLFIRI with and without bevacizumab in the community setting
Authors: Fortner BV, Schwartzberg LS, Stepanski EJ, Houts AC
Practice patterns of community based adjuvant hormonal therapy (AHT) in early stage breast cancer (ESBC)
Authors: Schwartzberg LS, Cobb P, Kulig K, Walker MS, Stepanski EJ, Fortner BV
Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation
Authors: Fortner B, Baldwin S, Schwartzberg L, Houts AC
Patient survey of the impact of toxicities with FOLFOX + Bevacizumab (BV) in 1st line metastatic colorectal cancer (MCRC) in the community oncology setting
Authors: Stepanski E, Fortner BV, Burns C, Johns A, Kulig K, Schwartzberg LS
The Cancer Care Monitor: Psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients
Authors: Fortner B, Okon T, Schwartzberg L, Tauer K, Houts AC
No Results
No publications match those filters.
Try clearing search terms or choosing a different filter combination.